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ABSTRACT 
A Study of Drug Utilization Pattern and Adverse Drug Reaction Profile of 
Antihypertensive Drugs Prescribed in a Tertiary Care Hospital 
Navaneeth A1, Rema Menon N2, Kaniraj Peter J3, Madhavrao C4 
1Postgraduate, 2Professor & HOD, 4Assistant Professor, Department of 
Pharmacology, 3Professor & HOD, Department of General Medicine, Sree 
Mookambika Institute of Medical Sciences [SMIMS], Kulasekharam, Kanyakumari 
District, Tamil Nadu -629161 
Introduction 
      Hypertension is an established risk factor for cardiovascular diseases with 
shortened expectancy of life. In this context, the use of established antihypertensive 
drugs assumes special importance. Various drug utilization pattern studies have been 
undertaken to provide useful feedback information to prescribers in order to establish 
the rational use of antihypertensive drugs. Accordingly, the present study in particular 
envisages the examination of the prescribing pattern, rationality and ADRs of 
antihypertensive drugs in a tertiary care hospital. 
Aims and objectives 
      To assess the pattern of prescription of antihypertensive drugs as monotherapy 
and combination therapy, the pattern by brand name and generic names, 
pharmacoeconomics of antihypertensive drugs prescribed, rationality of 
antihypertensive drugs prescribed and the adverse drug reaction profile of 
antihypertensive drugs. 
 
Materials and Methods 
      A cross-sectional study was conducted in Department of Medicine in a tertiary care 
hospital over a period of six months. The diagnosis and line of treatment to be given 
was decided by the treating physician. All the information about ADR was recorded in 
CDSCO Suspected ADR reporting form.  
Results 
      Out of 127 patients, 74.8% were female and 25.2% were male. Maximum patients 
belonged to age group of 61-70 years (51.18%). Diabetes mellitus (39.28%) was the 
most common associated disease with hypertension. About three fourth of the patients 
had received one antihypertensive drug (75.59%), followed by two (17.32%), three 
(5.51%) and four (1.58%) antihypertensive drugs. All the drugs were prescribed by 
brand name. Amlodipine was the most commonly prescribed antihypertensive drug. 
86 patients developed ADR to antihypertensive drugs. Metoprolol was the most 
expensive and furosemide was the least expensive drug prescribed as monotherapy. 
Amlodipine was responsible for most of the ADRs. ADRs associated with CNS 
(43.02%) were found to be most frequent. Headache was the commonest ADR 
followed by dizziness and pedal oedema. Majority of the ADRs were mild (87.21%).  
Conclusion 
      Rational utilization pattern of antihypertensive drugs was observed. However 
diuretics were prescribed less commonly. Most of the ADRs were mild (87.21%). 
Key words: Adverse drug reaction, drug utilization pattern, hypertension 
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1. Introduction: 
      Hypertension is a major public health problem due to increased morbidity, 
mortality and cost to the public.1 It is a major contributor to the global burden of 
diseases to the extent of 4.5% and it continues its upward growth trends.2 In 
2000 prevalence of hypertension in India was about 60 million males and 58 
million females; it is expected to become 107 million males and 106 million 
females in 2015. The prevalence of hypertension among urban population (4 - 
15%) is more than that among rural population (2 - 8%).3 It is an iceberg 
condition and the prevalence of hypertension has been considered as an 
increasing “silent killer” problem.4  
      Reasons for this growing trend is due to the unhealthy lifestyle practices, 
lack of awareness, distorted public health system, physicians not following the 
standard guidelines in treating hypertension and non-compliance to 
hypertension therapy.3 Keeping the blood pressure at an optimum level helps 
to prevent cardiovascular complications like stroke, myocardial infarction (MI), 
renal failure and mortality; this has been confirmed in epidemiological and 
interventional studies.5 
      In health economics, the major problems are the need of long term 
medication and the cost of the drug in the midst of high prevalence of 
hypertension. In developed countries, recently, there has been a sharp increase 
in the expenditure on antihypertensive therapy as many new and expensive 
drugs are coming out. Presence of comorbid conditions like diabetes mellitus 
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(DM) and hyperlipidemia further increases the treatment cost for the patients 
due to co-prescribing of long term medications for these conditions as well.5 
      Based on clinical evidence and cost effectiveness, the general principles of 
antihypertensive drug therapy as per the guidelines of Joint National Committee 
7 (JNC 7) and World Health Organization (WHO)–International Society of 
Hypertension (ISH) are as follows: initially monotherapy is started; 
subsequently, this is followed by combination therapy if required.6 Prescription 
pattern depends on age, gender and other comorbidities.7 It is recommended 
that diuretics, particularly the thiazides, are the first line treatment for 
uncomplicated hypertension. In complicated cases, CCBs and ACE inhibitors 
are indicated.8 On other hand, the European guidelines suggests if there is no 
specific indication, any of the five major classes of antihypertensive drugs can 
be started as first line treatment.8 For severe and uncontrolled hypertension, 
combination therapy is recommended as first line treatment. Many drugs in 
different combinations are used for long term treatment of hypertension.8 
      Changes overtime due to changes in treatment guidelines and availability of 
different drug formulations modifies the prescription pattern of antihypertensive 
drugs; thus, drug utilization studies comes to play. Drug utilization studies (DUS) 
help to analyze and evaluate the social, medical and economic outcomes of 
drug treatment; thus, they help to observe the prescribing attitude of physicians 
ultimately aiming at providing drug rationality; as the treatment is lifelong, the 
prescription needs special emphasis.8 
  Introduction 
3 | P a g e  
 
      Antihypertensive drugs are more prone for development of adverse drug 
reactions (ADRs); this decreases the available treatment options and also 
reduces the compliance of the patients; this in turn hinders blood pressure 
control.9 Hypertension is a disorder that requires long term therapy; this 
predisposes to ADRs.10 As many studies do not include pregnant ladies, the 
elderly and patients with many diseases, the study population may not be the 
real world where drug has to be used eventually; hence, safety monitoring has 
to be done to get information regarding ADRs to have a better treatment module 
and to prevent morbidity and mortality due to ADRs.11 Currently, ADR 
monitoring in India is in its infancy stage.10 
      Many new antihypertensive drugs are now available, which alter quality of 
life of the patient in a better way. Thus a regular scrutinization is needed by 
systematic audit that gives feedback to doctors, which will help to prescribe 
drugs rationally and to avoid ADRs.2 
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2. Justification:       
      Regular studies on drug utilization pattern are important to promote 
prescription of drugs rationally, to increase therapeutic efficacy, to decrease 
the cost, to decrease the ADRs and to give feedback to the prescribing 
doctors. Thus the main aim of drug utilization studies is to enable the rational 
use of drugs in the population. They also help to frame hypotheses that set 
the outline for further studies and thus help to prevent irrational use of drugs. 
They create a strong socio-medical and economic foundation for taking 
decisions regarding healthcare.8 
       At present there is an increasing trend for irrational prescribing of 
antihypertensive drugs. This will increase the cost burden on the health care 
system; hence, it is very essential to analyse the prescribing patterns and 
whether the prescribing doctors are following treatment guidelines.2 
      It is very essential to regularly monitor for ADRs in chronic conditions like 
hypertension. But DUS and ADR studies have not been reported so far in 
our institution. Hence, this study was undertaken as data from this part of 
South India are not much available and lacunae can be filled up to some 
extent with this study.  
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3. Aims and objectives: 
      To assess the following in the Department of Medicine, Sree 
Mookambika Institute of Medical Sciences, Kulasekharam, Tamilnadu during 
the period from October 2013 to March 2014: 
 The pattern of prescription of antihypertensive drugs as monotherapy 
and combination therapy 
 The pattern by brand name and generic names 
 The pharmacoeconomics of antihypertensive drugs prescribed 
 Rationality of antihypertensive drugs prescribed 
 The adverse drug reaction profile of antihypertensive drugs 
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4.1. Hypertension: 
4.1.1. Introduction12: 
      Hypertension is a long lasting condition of concern as it is responsible for 
causation of atherosclerotic heart disease and cerebrovascular accident 
(CVA). It is one of the main risk factors leading to cardiovascular 
complications. 
4.1.2. History13: 
     Thomas Young in 1808 was the first person to describe hypertension as 
a disease. In 1900, Treupel used sodium thiocyanate in the treatment of 
hypertension. Fritz Bruening performed the first sympathectomy operation 
for hypertension in 1923. Otto Frank in 1925 introduced the concept of 
essential hypertension. Physicians from the Mayo Clinic in 1928 coined the 
term malignant hypertension. In 1957 Freis introduced chlorothiazide in the 
treatment of hypertension; this was the first orally effective diuretic. 
4.1.3. Definition14: 
      Hypertension is defined according to JNC 7 and WHO/ISH guidelines as 
systolic blood pressure of ≥ 140 mm Hg and diastolic blood pressure of ≥ 90 
mm Hg, though the risk appears to increase even with blood pressure above 
120/80 mm Hg. 
4.1.4. Epidemiology12,15: 
      In developed countries, diastolic pressure is more than 90 mm Hg in 
about 25% adults; this prevalence is almost same in developing countries, 
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where it is seen in 10% to 20% adults. Hypertension accounts for 20-50% of 
all deaths. 
      Hypertension is present in all populations and it steadily increases during 
the first two decades of life. With advancing age, the prevalence of 
hypertension also increases. Systolic blood pressure is higher for adult 
males than females, but in older individuals, the age related rate rise is 
steeper for females. A middle aged or elderly individual has 90% chance of 
developing hypertension in his or her lifetime. Both genetic and 
environmental factors play a major role to produce regional and racial 
changes in blood pressure and prevalence of hypertension. 
      In India the prevalence of hypertension was 35 in males and 36 in 
females per 1000 in rural population and 60 in males and 70 in females per 
1000 in the urban population. 
4.1.5. Classification16: 
4.1.5. A. Essential or primary hypertension: 
      A patient is said to have essential hypertension when no particular cause 
of hypertension can be found. 
4.1.5. B. Secondary hypertension: 
      A patient is said to have secondary hypertension when a particular 
cause of hypertension can be found. 
4.1.6. Risk factors12: 
      Risk factors of hypertension include age, gender, hereditary factors, 
race, overweight, increased salt and saturated fat intake, decreased intake 
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of dietary fiber, alcohol consumption, sedentary lifestyle, high socio-
economic status and environmental stress. 
4.1.7. Etiopathogenesis: 
4.1.7. A. Genetic considerations15: 
      In rare Mendelian forms of hypertension lot of definite genetic variants 
have been found. These are applicable only to less than 2% of patients with 
essential hypertension. For many patients, hypertension is a polygenic 
disorder where in many genes act together with ecological factors; each 
gene has only a minimal role in causation of blood pressure. 
      Recent evidence proposes that genes that are components of the renin 
angiotensin aldosterone system (RAAS), together with ACE polymorphisms 
and angiotensinogen, may be associated with salt sensitivity of blood 
pressure and hypertension. Increased renal tubular reabsorption of sodium 
is believed to be related to the α-adducin gene; its variants may be related 
with blood pressure sensitivity to salt and hypertension. Other genes 
probably associated with hypertension are genes encoding the angiotensin II 
- type 1 (AT1) receptor, aldosterone synthase and the β2 receptor.15 
4.1.7. B. Mechanisms of hypertension: 
Intravascular volume15: 
      Vascular volume is a chief determining factor of blood pressure over the 
long term. Sodium is largely an extracellular ion and is a key determinant of 
the extracellular fluid volume. When intake of NaCl is more than the ability of 
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the renal system to excrete sodium, initially the vascular volume increases; 
this is followed by increase in cardiac output. 
      Increase in vascular volume causes increase in cardiac output which 
leads to the initial rise of blood pressure; in due course of time, the TPR 
increases and the cardiac output reverts back to normal. As high salt intake 
increases blood pressure, the kidney excretes more sodium; thus, the 
increase in arterial pressure maintains sodium balance. Decrease in 
absorbing capacity of the renal tubules, increase in the glomerular filtration 
rate (GFR) and hormonal factors such as atrial natriuretic factor are the 
causes for "pressure-natriuresis" phenomenon. 
Autonomic nervous system15: 
      Cardiovascular homeostasis is maintained by autonomic nervous system 
(ANS) by pressure, volume and chemoreceptor signals. Short term 
regulation of blood pressure is by adrenergic reflexes; long term regulation 
of arterial pressure is by adrenergic function along with hormonal and 
volume related factors. The catecholamines, noradrenaline, adrenaline and 
dopamine (DA), play important roles in cardiovascular regulation. 
      Guanosine nucleotide binding regulatory proteins (G proteins) and 
intracellular concentrations of second messengers bring about the actions of 
the adrenergic receptors. Noradrenaline activates α receptors more than 
adrenaline and adrenaline activates β receptors more than noradrenaline. In 
smooth muscles α1 receptors are present in postsynaptic cells; stimulation of 
these receptors brings about smooth muscle contraction. In postganglionic 
nerve terminals, α2 receptors are located on presynaptic membranes; 
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stimulation of these receptors reduces the release of noradrenaline from the 
nerve terminals. Negative feedback of α2 receptors comes into play when 
activated by catecholamines, thus preventing further noradrenaline release. 
Stimulation of myocardial β1 receptors increases cardiac contraction and 
cardiac output; stimulation β1 receptors on Juxtaglomerular cells increases 
renin release from the kidney. Vascular smooth muscle relaxation and 
vasodilation are brought about by activation of β2 receptors by adrenaline. 
      Blood pressure is regulated by several reflexes, of which baroreceptor 
reflex is facilitated by sensory nerve endings, aortic branch of vagus nerve, 
carotid branch of glossopharyngeal nerve present in the aortic arch and the 
carotid sinuses; these nerve endings are sensitive to stretch. Increase in 
arterial pressure stimulates these nerve endings; this causes decrease in 
sympathetic outflow, leading to decrease in heart rate and blood pressure. 
Renin angiotensin aldosterone system15: 
      The RAAS causes regulation of blood pressure by angiotensin II (Ang II) 
(which has vasoconstrictor property) and aldosterone (which has sodium 
retaining property). Renin is produced as an enzymatically inactive 
precursor, prorenin. There are three primary stimuli for renin secretion 
i. Decrease in NaCl flux across the macula densa 
ii. Decrease in pressure within the renal afferent arteriole 
iii. Stimulation of renin secreting cells (Juxtaglomerular cells) by β1 
receptors 
      In the circulation, active renin converts angiotensinogen to inactive 
angiotensin I (Ang I). Angiotensin converting enzyme which is present 
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mainly on the luminal surface of pulmonary endothelial cells, converts Ang I 
to Ang II (active form). The same enzyme inactivates the vasodilator 
bradykinin. Ang II is a potent pressor substance that acts through AT1 
receptors on cell membranes. Ang II is also involved in the pathogenesis of 
atherosclerosis. 
Vascular mechanisms15: 
      The key determinants of blood pressure are luminal size of resistance 
vessels (small arteries and arterioles) and elasticity of arteries. Even a small 
decrease in lumen size will greatly increase resistance. In hypertensive 
patients, the lumen size of small arteries and arterioles are reduced due to 
mechanical, structural or functional changes. Increased TPR occurs due to 
decrease in lumen size caused by hypertrophic or eutrophic vascular 
remodeling. Remodeling is also caused by low grade inflammation, 
apoptosis and vascular fibrosis. In a highly elastic vessel, even when the 
volume increases, there is only a little increase in pressure; in a semi rigid 
vessel, even with a small increase in volume, the pressure increases greatly. 
      Hypertensive patients have stiffer arteries and arteriosclerotic patients 
have decreased vascular compliance due to structural changes; this leads to 
high systolic blood pressures and wide pulse pressures. Hypertension 
related abnormalities of vascular growth and vascular tone is caused by ion 
transport by vascular smooth muscle cells, both of which are regulated by 
intracellular pH. 
i. Na+ dependent HCO3– Cl– exchange 
ii. Na+ H+ exchange 
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iii. Cation independent HCO3– Cl– exchange 
      These ion channels participate in the regulation of intracellular pH. 
      Na+ H+ exchanger activity is increased in hypertension; this in turn 
causes increase in vascular tone either by increasing sodium entry which in 
turn leads to an increase in intracellular calcium or by increasing intracellular 
pH which leads to an increase in contractility for a given concentration of 
intracellular calcium. The vascular endothelium synthesizes and releases 
vasoactive substances like nitric oxide, a potent vasodilator which modulates 
vascular tone. This is impaired in hypertensive patients.  
4.1.8. Clinical features15: 
      Most hypertensive patients will not have any specific symptoms. 
Headache is the commonest symptom seen in patients with severe 
hypertension; other symptoms include palpitations, dizziness, impotence and 
easy fatigability. 
4.1.9. Pathologic consequences: 
Heart15: 
      Heart disease is the most common cause of mortality in hypertensive 
individuals. It occurs due to functional and structural changes which causes 
left ventricular hypertrophy (LVH), coronary artery disease (CAD), chronic 
heart failure (CHF), cardiac arrhythmias and micro vascular disease. 
Patients with LVH have high possibility for CAD, CHF, CVA and unexpected 
death. CHF may be due to diastolic dysfunction or systolic dysfunction or 
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both. Diastolic function abnormalities are common in hypertensive patients; 
these may range from asymptomatic heart disease to heart failure. 
Brain15: 
      CVA is the second common cause of mortality. CVA mainly occurs due 
to infarction, but may also occur due to subarachnoid or intracerebral 
hemorrhage. In elderly individuals the increase in systolic blood pressure 
increases the incidence of CVA. 
      Impaired cognition is seen in elderly hypertensive individuals. Due to 
auto regulation, blood flow to the brain remains constant over a wide range 
of arterial pressures. When this auto regulation fails, patients develop 
encephalopathy; and they present with headache, nausea, projectile 
vomiting, focal neurologic signs and altered mental status. If untreated, it 
may progress to seizures, stupor, coma and sudden death. 
Kidney15: 
      Hypertension can lead to renal injury and end-stage renal disease. Renal 
risk is more with systolic arterial pressure and less with diastolic arterial 
pressure. Reliable marker for severity and progression of chronic kidney 
disease is proteinuria. 
      Preglomerular arterioles are affected in atherosclerotic hypertensive 
vascular disease of the kidney; this leads to ischemic alterations in 
glomerulus and post glomerular structures. Hyper perfusion of glomerulus 
occurs due to direct damage to the glomerular capillaries; this leads to 
glomerular injury. Auto regulation of renal blood flow and GFR fail with 
progression of renal injury: this leads to low blood pressure threshold for 
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renal damage. This causes further renal damage and nephron loss, which 
leads to severe hypertension and glomerular hyperfiltration. 
Glomerulosclerosis occurs and renal tubules become ischemic and atrophic. 
Fibrinoid necrosis of afferent arterioles are seen in malignant hypertension; it 
may extend to glomerulus and cause localized necrosis of glomerular tuft. 
Peripheral arteries15: 
      Longstanding elevated blood pressure will lead to atherosclerotic 
changes in blood vessels. Increased risk of cardiovascular disease is seen 
in patients with arterial diseases of lower limb. The main symptom of 
peripheral arterial disease is intermittent claudication. 
4.1.10. Diagnosis14,15: 
      Multiple automated ambulatory blood pressure readings recorded for 24 
hours or more give accurate data than few readings taken in the clinic; they 
give better idea about target organ damage. Treatment should be given 
accordingly because ambulatory blood pressure readings are lower by 12/7 
mm Hg than regular measurements. Treatment is decided based on average 
ambulatory daytime readings. 
      Diagnosis of hypertension is confirmed by a complete history and 
physical examination. Screening is done to find out any other cardiovascular 
risk factors, cardiovascular consequences of hypertension and secondary 
causes of hypertension. 
Basic laboratory tests for initial evaluation: 
i. Kidney: Microscopic urine analysis, urine albumin, renal function test 
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ii. Endocrine: Serum electrolytes and thyroid profile 
iii. Metabolic: Blood glucose level and lipid profile 
iv. Other: Haematology and electrocardiogram 
4.1.11. Treatment: 
Lifestyle interventions15: 
      Lifestyle changes help in prevention and treatment of hypertension. 
Hence, they are advised for individuals with prehypertension and for 
hypertensive individuals as an addition to drugs. 
Lifestyle changes to manage hypertension15: 
 Reduction of Weight with body mass index (BMI) < 25 kg/m2 
 Salt restricted diet < 6 g of NaCl/day 
 Follow DASH (Dietary Approaches to Stop Hypertension) diet plan. 
Diet should include vegetables, fruits and  products with reduced 
amount of fat  
 Reduction of alcohol consumption 
 Regular physical activity 
Pharmacotherapy15: 
      Drug therapy is recommended for individuals with blood pressure 
≥140/90 mmHg. Choice of antihypertensive agents and their combinations 
should depend on age, severity of hypertension, cardiovascular risk factors, 
comorbid conditions, cost, side effects and frequency of dosing. The 
antihypertensive drugs include α-blockers, β-blockers, CCBs (calcium 
channel blockers), diuretics, ACE inhibitors (Angiotensin converting enzyme 
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inhibitors), ARBs (Angiotensin receptor blockers) etc.; these are either used 
as monotherapy or as combination therapy. 
4.2. Antihypertensive drugs: 
4.2.1. Introduction16: 
      Lowering of blood pressure by antihypertensive drugs helps to prevent 
blood vessel damage and to reduce morbidity and mortality.  
Antihypertensive drugs acts by interfering normal arterial pressure 
regulation. Knowledge of mechanisms of antihypertensive drugs helps to 
predict their efficacy and toxicity resulting in rational use of these drugs.16 
4.2.2. Classification of antihypertensive drugs17: 
4.2.2.1. Diuretics: 
i. Thiazides and related agents: Hydrochlorothiazide, chlorthalidone, 
chlorothiazide, indapamide, methylclothiazide and metolazone. 
ii. Loop diuretics: Furosemide, torsemide, bumetanide, and ethacrynic 
acid. 
iii. K+ sparing diuretics: Spironolactone, amiloride and triamterene. 
4.2.2.2. Sympatholytic drugs: 
i. β-blockers: Metoprolol, betaxolol, nadolol, bisoprolol, esmolol, timolol, 
nebivolol, penbutolol, atenolol, pindolol and propranolol. 
ii. α-blockers: Prazosin, terazosin, doxazosin, phenoxybenzamine and 
phentolamine. 
iii. Mixed α and β receptor blockers: Labetalol and carvedilol. 
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iv. Centrally acting adrenergic agents: Methyldopa, clonidine, guanabenz 
and guanfacine. 
v. Adrenergic neuron blocking agents: Guanadrel and reserpine. 
4.2.2.3. Calcium channel blockers: 
      Verapamil, diltiazem, felodipine, nicardipine, isradipine, amlodipine and 
nifedipine. 
4.2.2.4. Angiotensin converting enzyme inhibitors: 
      Captopril, ramipril, enalapril, lisinopril, quinapril, trandolapril, fosinopril, 
benazepril and perindopril. 
4.2.2.5. Angiotensin receptor blockers: 
      Losartan, candesartan, irbesartan, valsartan, telmisartan, eprosartan and 
olmesartan. 
4.2.2.6. Direct renin inhibitor: 
      Aliskiren 
4.2.2.7. Vasodilators: 
i. Arterial: Hydralazine, minoxidil, diazoxide and fenoldopam 
ii. Arterial and venous: Nitroprusside 
4.2.2.1. Diuretics: 
i. Thiazides diuretics16-18: 
      Thiazides diuretics have antihypertensive effects when used alone; they 
enhance the efficacy of almost all other antihypertensive drugs.  
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 Mechanism of action16: 
      Initially thiazides decrease extracellular volume by interacting with a 
thiazide sensitive NaCl co-transporter present in the distal convoluted tubule 
(DCT) in the kidney, enhancing Na+ excretion in the urine, and leading to a 
fall in cardiac output. However, the hypotensive effect is maintained during 
long term therapy due to reduced TPR; cardiac output returns to 
pretreatment values and ECF volume returns almost to normal due to 
compensatory responses such as activation of RAAS. 
Pharmacokinetics17: 
      All thiazides are administered orally as they are well absorbed by this 
route. Onset of action is less than 1 hour; duration of action varies from 6-48 
hours. Most of the drugs undergo minimal metabolism in the liver and are 
excreted as such. They are filtered at the glomerulus; they are also secreted 
in the proximal tubule by organic anion transporter. 
Adverse drug reactions18: 
      Central nervous system adverse effects include vertigo, headache, 
weakness, xanthopsia and paresthesias. Gastrointestinal adverse effects 
include nausea, vomiting, anorexia, constipation, cramping, diarrhea, 
cholecystitis and pancreatitis. Hematological disorders (e.g. blood 
dyscrasias), dermatological disorders (e.g. photosensitivity and skin rashes) 
and erectile dysfunction also occur. Adverse effects related to fluid and 
electrolyte balance include extracellular volume depletion, hypotension, 
hyponatremia, hypokalemia, hypochloremia, hypomagnesemia, metabolic 
alkalosis, hyperuricemia and hypercalcemia. Glucose tolerance is impaired; 
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thus, latent diabetes mellitus may be unmasked during therapy. Thiazides 
also causes increase the plasma levels of triglycerides, low-density 
lipoprotein (LDL) cholesterol and total cholesterol. 
Contraindications18: 
      Thiazide diuretics are contraindicated in individuals hypersensitive to 
sulfonamides. 
Drug interactions18: 
      Thiazide diuretics decrease the effects of sulfonylureas, anticoagulants, 
insulin and uricosuric agents. They increase the effects of anesthetics, 
digitalis glycosides, diazoxide, loop diuretics, lithium and vitamin D. The 
effectiveness of thiazide diuretics may be reduced by nonsteroidal 
antiinflammatory drugs, nonselective or selective cyclooxygenase-2 (COX-2) 
inhibitors and bile acid sequestrants. Risk of thiazide induced hypokalemia is 
increased by amphotericin B and corticosteroids. A potentially lethal drug 
interaction is that involving thiazides and quinidine.Thiazides increase the 
risk of quinidine induced torsades de pointes.  
Therapeutic uses16: 
      Thiazide diuretics are used for the treatment of renal, hepatic and 
cardiac oedemas, in hypertension (either alone or in combination with other 
antihypertensive drugs), calcium nephrolithiasis, osteoporosis, nephrogenic 
diabetes insipidus and bromide intoxication. 
Dose17: 
      Thiazides are administered once daily. Common dose for hypertension is 
25 mg/day of hydrochlorothiazide. 
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ii. Loop diuretic17,18: 
      Furosemide is the prototype drug of loop diuretics. It acts by inhibiting 
the Na+ K+ 2Cl– symporter in the thick ascending limb of the loop of henle, 
and block its function, bringing salt transport in this segment of the nephron 
to a virtual standstill. Furosemide causes fall in blood pressure due to 
reduction of plasma volume and cardiac output. As the concentration of loop 
diuretic in the tubular lumen decreases, nephrons start to reabsorb Na+, 
which often abolishes the whole effect of the loop diuretic on total body Na+; 
this is called "postdiuretic Na+ retention" phenomenon; it can be overcome 
by regular administration of the loop diuretics and salt restricted diet. 
Pharmacokinetics17,18: 
      Furosemide is rapidly absorbed orally; bioavailability is about 60%. Lipid 
solubility is low; it is highly bound to plasma proteins. It is partly conjugated 
with glucuronic acid and mainly excreted unchanged by glomerular filtration 
as well as tubular secretion. Plasma t1/2 is 1-2 hours.  
Adverse effects17,18: 
      Adverse effects of loop diuretics are extracellular fluid volume depletion, 
hypokalemia, hypochloremic alkalosis, hyponatremia, hypomagnesemia, 
hypocalcemia and deleterious effects on bone metabolism. Loop diuretics 
also cause ototoxicity, hyperuricemia, hyperglycemia, increased plasma 
levels of triglycerides and LDL cholesterol and decreased plasma HDL (high 
density lipoprotein) cholesterol levels, photosensitivity, skin rashes, 
paresthesias, bone marrow depression and gastrointestinal upset. 
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Contraindications17,18: 
      Loop diuretics are contraindicated in severe volume and Na+ depletion, 
patients sensitive to sulfonamides, anuria unresponsive to a test dose of 
loop diuretic and in postmenopausal osteopenic women. 
Drug interactions17,18: 
      Drug interactions of loop diuretics are seen with aminoglycosides, 
carboplatin, paclitaxel, anticoagulants, digitalis glycosides, lithium, 
propranolol, sulfonylureas, cisplatin, NSAIDs, probenecid, thiazide diuretics 
and amphotericin B. 
Therapeutic uses17,18: 
      Loop diuretics are used in the treatment of acute pulmonary oedema, 
CHF, hypertension, oedema of nephrotic syndrome, oedema and ascites of 
liver cirrhosis, in drug overdose to induce a forced diuresis, hypercalcemia, 
hyponatremia and oedema associated with chronic renal disease.  
Dose17,18: 
      Furosemide is given 20-80 mg once daily in the morning. In renal 
insufficiency, up to 200 mg 6 hourly has been given by intramuscular or 
intravenous route; in pulmonary oedema, 40-80 mg may be given 
intravenously. 
iii. Potassium sparing diuretics17: 
      Potassium sparing diuretics either antagonise aldosterone or directly 
inhibit Na+ channels in DCT and collecting duct cells to indirectly conserve 
K+. 
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A. Spironolactone (Aldosterone antagonist)17: 
      Spironolactone acts from the interstitial side of the tubular cell, attaches 
with the mineralocorticoid receptor and prevents the formation of 
aldosterone-induced proteins (AlPs) in a competitive manner. It has no effect 
on Na+ and K+ transport in the absence of aldosterone, while under normal 
circumstances, it increases Na+ and decreases K+ excretion. Spironolactone 
is a mild saluretic because majority of Na+ has already been reabsorbed 
proximal to its site of action. However, it antagonises K+ loss induced by 
other diuretics and slightly adds to their natriuretic effect. 
Pharmacokinetics17: 
      The oral bioavailability of spironolactone is 75%. It is highly plasma 
protein bound; it undergoes complete metabolism in liver. The t1/2 of 
spironolactone is 1-2 hours and the t1/2 of its active metabolite canrenone is 
18 hours. 
Dose17: 25-50 mg twice to four times per day. 
Use17: 
      Spironolactone is used in oedema and to counteract K+ loss due to 
thiazide and loop diuretics. It is also used in hypertension only as adjuvant to 
thiazides to prevent hypokalaemia. It is also used in moderate to severe 
CHF as an additional drug to conventional therapy. 
Drug interactions17: 
      Drug interactions of spironolactone are seen with K+ supplements, 
aspirin, ACE inhibitors, ARBs and digoxin. 
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Adverse effects17: 
      Adverse effects of spironolactone are drowsiness, confusion, abdominal 
upset, hirsutism, gynaecomastia, impotence, menstrual irregularities, 
hyperkalaemia, acidosis and aggravation of peptic ulcer. 
B. Inhibitors of renal epithelial Na+ channel17,18: 
      Triamterene and amiloride are two inhibitors of renal epithelial Na+ 
channel with identical actions. 
Mechanism of action17,18: 
      The luminal membrane of late DCT and collecting duct cells expresses a 
distinct 'amiloride sensitive' or 'renal epithelial' Na+ channel, through which 
Na+ enters the cell down its electrochemical gradient, which is generated by 
Na+ K+ ATPase operating at the basolateral membrane. This Na+ entry 
partially depolarizes the luminal membrane, creating a transepithelial 
potential difference which promotes K+ secretion into the lumen through K+ 
channels. Though there is no direct coupling between Na+ and K+ channels, 
the more the delivery of Na+ to the distal nephron, the greater is its entry 
through the Na+ channel, the greater is the extent of depolarization of the 
luminal membrane, the greater is the driving force for K+ excretion. 
Pharmacokinetics17,18: 
      Triamterene is incompletely absorbed orally, partly bound to plasma 
proteins, largely undergoes hepatic metabolism and excreted in urine. 
Plasma t1/2 is 4 hours; the effect of a dose lasts for 6-8 hours. 
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Adverse effects17,18: 
      Nausea, dizziness, muscle cramps, rise in blood urea, impaired glucose 
tolerance and photosensitivity. 
Use17,18: Triamterene is used in treatment of hypertension and oedema. 
Dose17,18: 50-100 mg daily 
4.2.2.2. Sympatholytic drugs: 
i. Beta blockers17,18: 
      Adrenergic responses brought by β receptors are inhibited by β blockers. 
All β blockers act as competitive antagonists. It is also an inverse agonist. 
Mechanism of action17,18: 
      Propranolol acts by blocking β1 and β2 receptors; it weakly blocks β3 
receptor. Propranolol blocks vasodilatation and fall in blood pressure caused 
by isoprenaline and increases the rise in blood pressure caused by 
adrenaline. Vasomotor reversal (seen after α-blockade) is re-reversed. Only 
a small change in blood pressure is brought by its direct action on blood 
vessels. On long term administration blood pressure gradually falls in 
hypertensives but not in normotensives. Initially total peripheral resistance 
(TPR) is increased and cardiac output is reduced, so that there is only a 
small change in blood pressure. On long term administration, resistance 
vessels gradually adapt to chronically reduced cardiac output so that TPR 
falls; hence, both systolic and diastolic blood pressure fall. Other 
mechanisms involved are: 
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i. Decreased noradrenaline release from sympathetic terminals due to 
blockade of β2 receptors on presynaptic membrane. 
ii. Reduced renin release from renal system (β1 mediated): Propranolol 
causes a more marked fall in blood pressure in patients with normal or 
high plasma renin levels and these patients respond at comparatively 
lower doses than those with low levels of plasma renin. 
iii. Central action reducing sympathetic outflow.  
Pharmacokinetics17,18: 
      On oral administration, propranolol is well absorbed, but bioavailability is 
low due to high first pass metabolism in liver. It is lipophilic and penetrates 
into brain easily. Metabolism of propranolol is dependent on blood flow to the 
liver. Bioavailability can be increased by taking it with meals because food 
decreases its first pass metabolism. More than 90% of propranolol is plasma 
protein bound. The metabolites are excreted in urine, mostly as 
glucuronides. 
Dose17,18: 
      10 mg twice daily to 160 mg 6th hourly given orally, intravenously: 2 to 5 
mg injected over 10 min. 
Drug interactions17,18: 
      Drug interactions of propranolol are seen with digitalis, verapamil, insulin 
and oral antidiabetic drugs, phenylephrine, ephedrine, indomethacin, 
cimetidine, lidocaine and chlorpromazine. 
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Adverse effects and contraindications17,18: 
      Adverse effects of propranolol are bradycardia, worsening of chronic 
obstructive pulmonary disease (COPD), exacerbation of variant angina, 
impairment of carbohydrate tolerance in prediabetics, increase of total 
triglycerides and LDL cholesterol and reduction of HDL cholesterol, 
tiredness, reduced exercise capacity , deterioration of peripheral vascular 
disease, cold extremities, gastrointestinal upset, lack of drive, nightmares, 
forgetfulness, hallucinations and sexual distress. Withdrawal of propranolol 
after chronic use should be gradual as it may cause rebound hypertension, 
deterioration of angina and even sudden death. Propranolol is 
contraindicated in myocardial insufficiency, asthmatics and in partial and 
complete heart block. 
ii. α1 Adrenergic receptor antagonists
17,18: 
      The drugs that blocks only α1 receptors without blocking α2 receptors 
form one more group of antihypertensive drugs. Prazosin, terazosin, and 
doxazosin are the agents that are available for the treatment of 
hypertension. 
Mechanism of action17,18: 
      α1 adrenergic receptor antagonists are selective α1 blockers. All subtypes 
of α1 receptor (α1A, α1B, α1D) are blocked in the same way; this brings about 
vasodilation and fall in blood pressure. 
      Initially α1 receptor blockers decrease TPR and increase venous 
capacitance; this causes a reflex increase in heart rate and plasma renin 
activity. On long term treatment, only vasodilation persists; heart rate, 
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cardiac output and plasma renin activity return to normal. On long term 
therapy, salt and water retention occurs in many people; this attenuates the 
postural hypotension. 
Adverse Effects17,18: 
      The α1 adrenergic blockers cause postural hypotension, nasal blockade, 
headache, weakness, drowsiness, dry mouth, palpitation, rash, blurred 
vision and impaired ejaculation in males. 
Therapeutic Uses17,18: 
      α1 receptor blockers are not used as monotherapy for hypertensives; are 
used mostly in combination with β blockers, diuretics and other 
antihypertensive drugs. α1 receptor blockers are good drugs for hypertensive 
patients with BPH, because they also improve urinary symptoms. Prazosin 
improves carbohydrate metabolism, lowers LDL cholesterol and triglycerides 
and increases HDL. 
Pharmacokinetics17,18: 
      Prazosin is orally effective (bioavailability is 60%), highly plasma protein 
bound, undergoes hepatic metabolism and excreted mainly in bile. Its 
plasma t1/2 is 2-3 hours; the effect of a dose lasts for 6-8 hours.  
Dose17,18: 
      Initially prazosin is started at low dose (0.5 mg) given at bedtime and 
slowly increased to twice daily therapy till a sufficient response is produced 
(maximum dose of 10 mg twice daily). 
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iii. Mixed α and β Adrenergic blockers: 
Labetalol18: 
      Labetalol blocks both α and β receptors. It blocks β1 + β2 + α1; it also has 
weak β2 agonistic activity. It blocks β receptors 5 times more potently than α.  
Labetalol at low doses has effects like those of propranolol alone, but at high 
doses has effects that are like a combination of prazosin and propranolol. 
Fall in blood pressure (both systolic and diastolic) is due to blockade of α1 
and β1 and β2 agonistic activity. At high doses it reduces both TPR and 
cardiac output. On the contrary to propranolol, labetalol increases blood flow 
to the limbs. In adrenergic nerve endings it inhibits noradrenaline uptake by 
the nerve endings. Labetalol is effective orally but undergoes high first pass 
metabolism. It is only a moderately potent antihypertensive and is useful in 
clonidine withdrawal and pheochromocytoma. 
      Adverse reactions are rashes, postural hypotension, failure of ejaculation 
and liver damage. 
Dose: Initially start with 50 mg twice daily, escalate to 100-200 mg thrice 
daily orally. 20-40 mg intravenously every 10 min (until desired response) is 
given in hypertensive emergencies.  
Carvedilol17,18: 
      Carvedilol is a β1 + β2 + α1 blocker; it produces vasodilatation due to α1 
blockade and calcium channel blockade, but it lacks intrinsic 
sympathomimetic activity; it also has antioxidant property. It is used in 
hypertension; is the β blocker used in CHF as cardioprotective. Carvedilol 
combined with usual therapy reduces mortality and reduces MI. 
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Pharmacokinetics17,18: 
      On oral administration, carvedilol is well absorbed; peak plasma levels 
are attained at 1-2 hours. It is highly lipophilic and thus, is extensively 
distributed into extravascular tissues. It is > 95% protein bound and is 
extensively metabolized in the liver. The t1/2 is 7-10 hours. 
Drug interactions17,18: 
      Carvedilol undergoes extensive oxidative metabolism in the liver; its 
pharmacokinetics can be markedly affected by drugs that inhibit or induce 
oxidation. These include the inducer rifampicin and inhibitors such as 
cimetidine, quinidine, fluoxetine and paroxetine. 
Uses17,18: 
      Carvedilol is used in hypertension, CHF and left ventricular dysfunction 
following MI. 
 CHF: Start with 3.125 mg twice daily for 2 weeks; if well tolerated 
gradually increase to a maximum of 25 mg twice daily. 
 Hypertension/angina: Start with 6.25 mg twice daily; gradually increase 
to a maximum of 25 mg twice daily. 
iv. Central sympatholytics: 
Clonidine18: 
      Clonidine is an imidazoline derivative having complex actions. Clonidine 
is a partial agonist with high affinity and high intrinsic activity at α2 receptors, 
especially α2A subtype in brainstem. The major hemodynamic effects result 
from stimulation of α2A receptors present mainly postjunctionally in 
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vasomotor centre of medulla; this decreases sympathetic out flow, resulting 
in fall in blood pressure and bradycardia. Plasma noradrenaline also 
declines. Clonidine is a moderately potent antihypertensive. Presence of 
imidazoline receptors (which are distinct from α2 receptors) has now been 
confirmed in the brain as well as periphery. These are activated by clonidine 
and related drugs but not by noradrenaline. Clonidine may stimulate central 
imidazoline receptors; these receptors then stimulate medullary α2A 
receptors to reduce sympathetic outflow. Clonidine also appears to directly 
stimulate α2A receptors (producing hypotension as well as sedation). 
Rilmenidine and moxonidine are selective cerebral imidazoline receptor 
agonists with low α2A receptor affinity. Therefore, they have low sedative 
property but equivalent antihypertensive action. 
      Rapid intravenous injection of clonidine raises blood pressure transiently 
due to activation of peripheral postsynaptic vasoconstrictor α2B receptors at 
the high concentrations so attained. Oral doses producing lower plasma 
clonidine levels cause only fall in blood pressure, because clonidine has 
lower intrinsic activity on α2B receptors which predominate in vascular 
smooth muscle. Probably for the same reason, clonidine exhibits the 
therapeutic window phenomenon: optimum lowering of blood pressure 
occurs between blood levels of 0.2-2.0 ng/ml. At higher concentrations, fall 
in blood pressure is less marked. On chronic administration of clonidine, 
decrease in cardiac output contributes more to the fall in blood pressure than 
decrease in TPR. Decreased sympathetic flow to the kidney results in 
reduced renin release. 
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Pharmacokinetics18: 
      On oral administration clonidine is well absorbed; it attains peak plasma 
levels in 2-4 hours; 1/2 to 2/3 of an oral dose is excreted unchanged in urine, 
the rest as metabolites. Plasma t1/2 is 8-12 hours. Effect of a dose lasts for 6-
24 hours. 
Dose18: 
      100 µg once or twice daily, maximum 300 µg thrice daily, orally or 
intramuscularly. 
Adverse effects18: 
      Adverse effects of clonidine are sedation, mental depression, disturbed 
sleep, dryness of mouth, nose and eyes, constipation, impotence, salt and 
water retention, bradycardia and postural hypotension. Alarming rise in 
blood pressure, in excess of pretreatment level, with tachycardia, 
restlessness, anxiety, sweating, headache, nausea and vomiting occur in 
some patients when doses of clonidine are missed for 1-2 days. This is due 
to: 
 Sudden removal of central sympathetic inhibition resulting in release of 
large quantities of stored catecholamines. 
 Supersensitivity of peripheral adrenergic structures to catecholamines 
that develops due to chronic reduction of sympathetic tone during 
clonidine therapy.  
      A combination of α blocker with a β blocker or a potent vasodilator or 
clonidine itself can be used to treat the syndrome. 
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Interactions18: 
      Tricyclic antidepressants and chlorpromazine abolish the 
antihypertensive action of clonidine by blocking α-receptors on which 
clonidine acts. 
Use18: 
      Clonidine is occasionally used in treatment of hypertension (in 
combination with a diuretic) and for opioid withdrawal, alcohol withdrawal 
and smoking cessation. It has been used to substitute morphine for 
intrathecal/epidural surgical and postoperative analgesia. When 
administered preoperatively, it diminishes anaesthetic requirement. 
Clonidine attenuates vasomotor symptoms of menopausal syndrome. It has 
been used to control loose motions due to diabetic neuropathy; it is used in 
the clonidine suppression test for pheochromocytoma. 
V. Adrenergic neuron blockers: 
Reserpine18: 
      Reserpine is an alkaloid obtained from the roots of Rauwolfia serpentina. 
It has been used in 'Ayurvedic' medicine for centuries. In 1955 the pure 
alkaloid was isolated; later, it was found to act by causing depletion of 
catecholamines and 5-hydroxytryptamine. In late 1950s and early 1960s, it 
was a popular antihypertensive drug; but at present, it is used only as a 
pharmacological tool. Monoamines are stored in intra neuronal vesicles. 
Reserpine acts by irreversibly inhibiting the vesicular monoamine transporter 
(VMAT2) located on the membrane of these vesicles; therefore, the 
monoamines are not taken up by the vesicles. In the cytoplasm, they are 
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metabolized by monoamine oxidase (MAO); the net result is depletion of 
monoamines from storage vesicles. Even after drug is eliminated, the effects 
last for a long time; hence, it is called “hit and run drug”; this is because 
tissue catecholamine stores are restored only gradually. At higher doses, it 
depletes catecholamines and 5-hydroxytryptamine in the brain as well; this 
causes sedation and mental depression. 
4.2.2.3. Calcium channel blockers18: 
      Important classes of CCBs include phenyl alkylamines (e.g. verapamil), 
dihydropyridines (e.g. nifedipine) and benzothiazepines (e.g. diltiazem). All 
the three classes are equally efficacious antihypertensive drugs. 
Calcium channels18: 
      In smooth muscles (other excitable cells as well), three types of Ca2+ 
channels are seen 
a) Voltage sensitive channels (three major types include L-type, T-type 
and N-type channels)  
b) Receptor operated channels 
c) Leak channels 
      L-type calcium channels are composed of a major α1 subunit and other 
modulatory subunits like α2, β, γ and δ. Each subunit has multiple isoforms; 
these isoforms may be site specific. CCBs block only the L-type channels. 
The three classes of CCBs bind to their own specific binding sites on the α1 
subunit; by doing so restrict Ca2+ entry. Also, different drugs have different 
affinities for various isoforms of L-type channels. In cardiac or smooth 
muscle cell, CCBs inhibit Ca2+ mediated slow channel part of action potential 
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(AP), causing negative inotropic, chronotropic, and dromotropic effects and 
relaxation of smooth muscle. Of the three classes of CCBs the DHPs have 
the most marked smooth muscle relaxant and vasodilator action; this is 
because they have additional effects such as inhibition of cAMP-
phosphodiesterase (which increases cAMP in smooth muscle).  
Nifedipine18: 
      Nifedipine is the prototype DHP, it has rapid onset and short duration of 
action. The principal action of nifedipine is dilatation of arterioles; hence, 
TPR reduces and blood pressure falls. At much higher doses, it has a direct 
depressant effect on heart. It does not affect A-V or SA node conduction. 
Reflex sympathetic stimulation of heart predominates leading to increased 
heart rate, myocardial contractility and cardiac output. Increased coronary 
flow is seen.  
Dose18: 
      5-20 mg twice daily to thrice daily orally. 
Adverse effects18: 
      Hypotension, palpitation, flushing, ankle oedema, headache, drowsiness 
and nausea; frequency of angina is increased; among post MI patients 
mortality is higher; increased urine voiding difficulty in elderly males; and 
hindrance to diabetes control (due to reduction of insulin release). 
Pharmacokinetics18: 
      All CCBs are well absorbed orally; they attain peak at 1 to 3 hours 
(except for amlodipine which attains peak level at 6 to 9 hours). Due to high 
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first pass metabolism, oral bioavailability is incomplete with striking individual 
variations. All are highly plasma protein bound. The CCBs have extensive 
tissue distribution and high clearance. All undergo hepatic metabolism and 
are excreted in urine. The elimination t1/2 are in the range of 2 to 6 hours (but 
the elimination t1/2 of amlodipine is exceptionally long).  
Uses18: 
      CCBs are used in angina pectoris, hypertension and cardiac 
arrhythmias. Nifedipine is used as an alternative drug for premature labour; 
verapamil is used to suppress nocturnal leg cramps; DHPs decrease 
severity of Raynaud's episodes. 
4.2.2.4. Angiotensin converting enzyme (ACE) inhibitors17,18: 
Mechanism of Action17,18: 
      Decreased sodium flux across macula densa, decreased renal arterial 
pressure and sympathetic stimulation cause release of renin from the 
juxtaglomerular apparatus. Renin converts angiotensinogen to inactive 
angiotensin I (Ang I). ACE which is present mainly on luminal surface of 
pulmonary endothelial cells, converts Ang I to Ang II (active form), which has 
sodium retaining and vasoconstrictor activities. Ang II is converted to 
angiotensin III by aminopeptidase A. Angiotensin II and III stimulate 
aldosterone secretion by zona glomerulosa. 
      ACE inhibitors prevent the generation of the active principle, angiotensin 
II. In patients with essential hypertension, it has been found that RAAS is 
overactive in 20%, normal in 60% and hypoactive in the rest. Thus, it 
contributes to the maintenance of vascular tone in over 80% of cases; in 
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these cases its inhibition results in lowering of blood pressure. In 
normotensive, Na+ replete individuals, the fall in blood pressure attending 
the initial few doses of ACE inhibitors is modest. This is more marked when 
Na+ has been depleted by dietary restriction or diuretics. A greater fall in 
blood pressure occurs in renovascular, accelerated and malignant 
hypertension. 
Pharmacokinetics17,18: 
      Nearly 70% of orally administered captopril is absorbed. If taken with 
food its bioavailability is decreased. It is partly metabolized and partly 
excreted unchanged in urine. The plasma t1/2 is 2 hours, but actions last for 6 
to 12 hours. 
Adverse effects17,18: 
      The adverse effects of ACE inhibitors include hypotension, 
hyperkalemia, cough, rashes, urticaria, angioedema, dysgeusia, headache, 
dizziness, nausea, bowel upset, granulocytopenia and proteinuria. Fetal 
growth retardation, organ hypoplasia and fetal death may occur if given 
during the later half of pregnancy. 
Contraindications17,18: 
      ACE inhibitors are contraindicated in patients with bilateral renal artery 
stenosis as they precipitate acute renal failure in these patients. 
Drug interactions17,18: 
      Indomethacin and other NSAIDs attenuate the hypotensive action. 
Incidents of renal failure have been reported when a NSAID was given to 
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patients receiving ACE inhibitor with diuretic. Hyperkalemia can occur if K+ 
supplements/K+ sparing diuretics are given with captopril. Antacids reduce 
bioavailability of captopril: ACE inhibitors reduce lithium clearance and 
predispose to its toxicity. 
Dose17,18: 
      25 mg twice daily, increased gradually upto 50 mg thrice daily according 
to response. In patients on diuretics and in CHF patients it is wise to start 
with 6.25 mg twice daily to avoid marked fall in blood pressure initially. 
Tablets are taken one hour before or two hours after a meal. 
Uses17,18: 
      ACE inhibitors are used in hypertension, CHF, MI, prophylaxis in high 
cardiovascular risk subjects, diabetic nephropathy and scleroderma crisis. 
4.2.2.5. Angiotensin receptor blockers18: 
     AT1 receptor blockers include losartan, candesartan, valsartan, 
telmisartan and irbesartan. Selective antagonists of AT2 receptors, as well as 
combined AT1 + AT2 antagonists have also been produced. 
Losartan18: 
      Losartan is competitive antagonist and inverse agonist of angiotensin II. 
It is more selective for AT1 than for AT2 receptor; it does not have action on 
any other ion channel or receptor, except thromboxane A2 receptor. It blocks 
all overt actions of angiotensin II, namely vasoconstriction, central and 
peripheral sympathetic stimulation, release of aldosterone and adrenaline 
from adrenals, renal actions promoting salt and water reabsorption, central 
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actions like thirst, vasopressin release and growth promoting actions on 
heart and blood vessels. Losartan causes fall in blood pressure in 
hypertensive patients which lasts for 24 hours, while heart rate remains 
unchanged and cardiovascular reflexes are not interfered. 
Pharmacokinetics18: 
      Food does not interfere with oral absorption of losartan; however, 
bioavailability is only 33% due to high first pass metabolism. It is partly 
carboxylated in liver to E3174; this active metabolite is a more potent 
noncompetitive AT1 receptor antagonist. After oral ingestion, peak plasma 
levels are attained at 1 hour for losartan and at 3 to 4 hours for E3174. Both 
compounds are 98% bound to plasma protein, do not cross blood brain 
barrier and are excreted by the kidney. The plasma t1/2 of losartan is 2 hours, 
but that of E3174 is 6 to 9 hours. No dose adjustment is required in renal 
insufficiency, but the dose should be reduced in presence of liver 
dysfunction. 
Adverse effects18: 
      Losartan is well tolerated. But it can cause hypotension, hyperkalemia, 
dry cough, angioedema, headache, dizziness, weakness and upper 
gastrointestinal side effects. It has fetopathic potential; it should be avoided 
during pregnancy. 
Dose18: 
      50 mg once daily; in liver disease or volume depletion, the dose is 25 mg 
once daily; addition of hydrochlorothiazide 12.5-25 mg enhances its 
effectiveness. 
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Uses18: 
      Used in hypertension, CHF, MI and diabetic nephropathy. 
4.2.2.6. Direct Renin Inhibitors17: 
      Like ACE inhibitors and ARBs, direct renin inhibitors are drugs that inhibit 
the renin angiotensin pathway; they have efficacy in the treatment of 
cardiovascular disease. Aliskiren is a direct renin inhibitor; it interrupts this 
pathway by inhibiting the capacity of renin to produce angiotensin I from 
angiotensinogen. 
      Aliskiren has been used as an add-on drug in patients with hypertension, 
rather than as a replacement for other successful therapies. 
Mechanism of Action17: 
      The initial renin inhibitors were peptide analogues of sequences either in 
renin itself or included the renin cleavage site in angiotensinogen. While 
effective in inhibiting renin and lowering blood pressure, these peptide 
analogues were effective only parenterally. However, aliskiren is effective 
following oral administration; it directly and competitively inhibits the catalytic 
activity of renin. 
Pharmacological Effects17: 
      Aliskiren's inhibition of renin leads to diminished production of Ang I and 
ultimately Ang II and aldosterone with a resulting fall in blood pressure. 
Aliskiren along with ACE inhibitors and AT1 receptor antagonists leads to an 
adaptive increase in the plasma concentrations of renin; but as aliskiren 
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inhibits renin activity, plasma renin activity does not increase as occurs with 
these other classes of drugs. 
Absorption, Metabolism, and Excretion17: 
      Aliskiren is poorly absorbed, with a bioavailability of < 3%. Taking the 
drug with a high-fat meal may substantially decrease plasma concentrations. 
Aliskiren has an elimination t1/2 of at least 24 hours. Elimination of the drug 
may be primarily through hepatobiliary excretion with limited metabolism via 
CYP3A4. 
Toxicity and Precautions17: 
      Aliskiren is generally well tolerated. ADRs includes diarrhoea, cough and 
angioedema. Drugs acting on the RAAS may damage the fetus and should 
not be used in pregnant women. 
Therapeutic Uses17: 
      Aliskiren is effective as monotherapy in treating patients with 
hypertension with dose dependent increasing efficacy at 150 to 300 mg/day. 
The combination of aliskiren with hydrochlorothiazide has a greater lowering 
effect on blood pressure than either drug alone. Aliskiren also appears to 
have greater efficacy when added to other agents in the treatment of 
hypertension including ACE inhibitors, ARBs and CCBs. Overall, aliskiren 
appears to be an effective antihypertensive drug that is well tolerated. 
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4.2.2.7. Vasodilators: 
i. Arterial vasodilators18: 
      Hydralazine dilates resistance vessels; it has little action on capacitance 
vessels. Therefore, it reduces TPR. It reduces diastolic blood pressure more 
than systolic blood pressure. This causes reflex compensatory changes, 
such as increase in heart rate, increase in cardiac output and renin release; 
this in turn increases aldosterone, which causes retention of Na+ and water. 
This disproportionate cardiac stimulation indicates that other actions, such 
as direct increase in noradrenaline release and myocardial contractility, are 
also involved. Despite the fall in blood pressure, renal blood flow is not 
decreased; but retention of fluid and oedema may occur. If β blockers or 
diuretics are not given with hydralazine, tolerance develops to its 
hypotensive action.  
Pharmacokinetics18: 
      Hydralazine is well absorbed orally. It undergoes first pass metabolism in 
the liver; the main pathway is acetylation. There are fast acetylators (30-40% 
of Indians) as well as slow acetylators (60-70% of Indians). Slow acetylators 
have higher bioavailability. Hydralazine undergoes complete metabolism 
both in liver and plasma; the metabolites are excreted in urine. t1/2 is 1-2 
hours; but the hypotensive effect lasts longer.  
Dose18: 
      25-50 mg once to thrice daily. 
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Adverse drug reactions18: 
      ADRs are conjunctival congestion, nasal stuffiness, facial flushing, 
headache, dizziness, palpitation, fluid retention, oedema and CHF.  It may 
precipitate MI and angina in patients with CAD. Other ADRs are 
paresthesias, tremors and muscle cramps. Lupus syndrome develops with 
prolonged use of doses above 100 mg/day. Slow acetylators are more prone 
to develop this syndrome. 
Uses18: 
      Hydralazine is used in hypertension uncontrolled by first line 
antihypertensive drugs. It is used only in combination with a diuretic and / or 
β blockers. It is one of the preferred antihypertensive drugs in pregnant 
women with pre-eclampsia. It is occasionally used in hypertensive 
emergencies. It can be used in the management of CHF (in combination with 
isosorbide dinitrate). 
Contraindications18: In elderly and in patients with ischemic heart disease.  
ii. Arterial and venous vasodilators: 
Sodium nitroprusside18: 
      Sodium nitroprusside is a vasodilator; the onset of action is rapid; the 
duration of action is short. It is administered intravenously as infusion. By 
adjusting the rate of intravenous infusion, the vascular tone can be adjusted. 
It is both an arteriolar and a venous dilator; therefore, it that decreases both 
TPR and venous return. Myocardial workload is decreased; ischemia risk is 
not accentuated. It increases plasma renin activity. In patients with CHF and 
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ventricular dilatation, nitroprusside reduces afterload and preload and thus, 
improves ventricular function and cardiac output. In RBC’s and endothelial 
cells, nitroprusside is split to release nitrous oxide both enzymatically and 
non-enzymatically; nitrous oxide relaxes vascular smooth muscle. This is the 
reason for the vasodilator action of nitroprusside. 
      In 500 ml of glucose/ saline solution, 50 mg of nitroprusside is added. 
The infusion is started at 0.02 mg/min and titrated upward the response; 0.1-
0.3 mg/ min is often needed. The infusion bottle is covered with black paper; 
this is because it decomposes on exposure to light.  Nitroprusside is 
converted in erythrocytes to cyanide; cyanide is converted in liver to 
thiocyanate, which is excreted slowly. Infusion of larger doses for 1-2 days 
may cause thiocyanate accumulation; this occurs particularly in patients with 
renal insufficiency; thiocyanate toxicity manifests as psychosis, disorientation 
and convulsions. 
Side effects18: 
      Excessive sweating, palpitation, nervousness, vomiting, abdominal pain, 
weakness, disorientation and lactic acidosis. 
4.3. Drug utilization studies: 
4.3.1. Introduction19: 
      Drug utilization studies are dominant investigative kit to learn the function 
of drugs in society. They generate a thorough socio-medical and strong 
economic base for making healthcare decision. 
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4.3.2. Definition20: 
     According to WHO drug utilization is defined as“the marketing, 
distribution, prescription and use of drugs in a society, with special emphasis 
on the resulting medical, social and economic consequences”. 
4.3.3. Objectives21: 
      The principal objective of DUS is to facilitate rational use of drugs in the 
population. 
1. To increase our understanding of how drugs are being used. 
2. To give an early signal of irrational use of a drug 
3. To analyse whether the steps taken to improve drug utility have had 
the required impact. 
4. To help the healthcare system to know, interpret, analyse and 
improve the drug prescription, use and administration of medication. 
5. To provide insight into the effectiveness of drug use. 
6. To set priority for sensible distribution of healthcare budgets  
4.3.4. Types of drug use information20: 
      In DUS the following drug use information are essential 
1. Drug based information 
2. Problem based information 
3. Patient information 
4. Prescriber information 
4.3.5. Drug utilization methods22: 
1. Methods used in qualitative studies 
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2. Studies on prescription habits 
3. Studies on patient compliance 
4. Studies on drug effects 
5. Studies on patients awareness about drugs 
6. Consumption studies 
7. Descriptive studies, effect of drug use and determinants of drug 
utilization  
4.3.6. Sources of drug utilization data20: 
      Data can be obtained from general practitioners, from pharmacy records, 
from drug regulatory agencies, from drug suppliers and straight from 
population through health surveys like surveys conducted among females, 
elderly out patients or at national level. 
4.3.7. Study designs for drug utilization studies20: 
      The study designs in DUS are 
 Prospective 
 Concurrent 
 Retrospective 
      Prospective DUS involves evaluating the patient’s disease and its 
intended drug therapy before a drug is given. It generally addresses generic 
substitution, drug-disease contraindications, therapeutic interchange and 
wrong dosage, improper duration of treatment, clinical abuse and drug 
allergy. 
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      Concurrent DUS involves monitoring of drug therapy which is on 
progress, to guarantee positive results. It addresses drug - age precautions, 
extreme dose, low or high dosage, over or underutilization, drug-drug 
interactions. 
      Retrospective DUS involves review of drug therapy after the patient has 
taken the drug. It may notice the prescribing pattern of the drugs, 
administering or dispensing drugs to avoid improper use of drugs. It includes 
case report, case series and case control studies. 
4.3.8. WHO drug use indicators20: 
4.3.8.A. Core indicators: 
a) Prescribing indicators: 
 Average number of medications per consultation 
 Percentage  of medications prescribed by generic name 
 Percentage of medications prescribed from essential drug list 
 Percentage of consultations with injections 
 Percentage of consultations with antibiotics 
b) Patient care indicators: 
 Average consultation time 
 Average dispensing time 
 Patient’s awareness about correct dosage 
 Percentage of drugs actually dispensed 
c) Facility indicators: 
 Availability of copy of EDL 
 Availability of important drugs 
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4.3.8.B. Complementary indicators: 
 Percentage of patients treated without medications 
 Average drug cost per consultation 
 Percentage of drug cost spent on injections 
4.3.9. Steps in drug utilization studies23: 
 Recognize therapeutic areas of practice or drugs to include in the 
program 
 Design of study 
 Define criteria and standards 
 Design the data collection form 
 Data collection 
 Evaluate results 
 Provide feedback of results 
 Develop and implement interventions 
 Reassess and revise the drug utilization evaluation program 
4.4. Pharmacovigilance: 
4.4.1. Introduction24,25: 
      In the recent trend, people are using more efficient and newer drugs for 
diverse medical conditions in large scale; these drugs are being produced 
with developing scientific advances. The two important concerns about any 
drug are efficacy and safety. The pharmacovigilance plays a vital role in 
rational use of drugs by giving details about the ADRs shown by the drugs in 
the general population. 
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4.4.2. Definition24: 
      WHO defined the Pharmacovigilance as the pharmacological science 
relating to the detection, evaluation, understanding and prevention of 
adverse effects, particularly long term and short term side effects of 
medicines. 
4.4.3. Objectives of phrmacovigilance25: 
 Expand precaution for patient. 
 Increase public protection from the new products. 
 To contribute the knowledge of value, detriment, efficiency and hazard 
of medicines. 
 Encourage edification and clinical training. 
 Endorse healthy communication to the community. 
 To promote rational and safe use of medicines. 
4.4.4. Current status of Pharmacovigilance in India24-28: 
      In the world, India stands fourth among producers of pharmaceuticals. It 
is rising as one of the clinical trial hub in the world. Our country introduces 
many new drugs and hence there is a need for an energetic 
pharmacovigilance system in the country to guard the people from the 
possible harm that may be caused by some of these new drugs. Evidently 
conscious about the extent of the task, the Central Drugs Standard Control 
Organization (CDSCO) has started a well planned and highly participative 
National Pharmacovigilance Program. It is mainly based on the 
recommendations made in the WHO document titled “Safety Monitoring of 
Medicinal Products Guidelines for Setting up and Running a 
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Pharmacovigilance Centre”. Pharmacovigilance has not come up well in 
India and the subject is in its early stage. The rate of pharmacovigilance in 
India is less than 1% when compared with the world rate of 5%. This is 
because of lack of knowledge about the subject and also deficiency in 
training. Now a days in India, pharmacovigilance situation has been 
progressing step by step than what it was in the past. 
4.5. Pharmacoeconomics18,29: 
      Pharmacoeconomics is the science of assigning costs and outcomes of 
drug therapy. Pharmacoeconomics includes the identification, measurement 
and comparison of the costs, risks, results and benefits of programmes, 
services or individual therapies. Its aim is to compare the alternative 
solutions available on the basis of the relationship between necessary 
resources and results to be obtained. This definition highlights two concepts 
of fundamental importance for application of the economic principle the 
possibility of choosing between alternatives and comparing on the basis of 
costs and effects. 
      There are four types of pharmacoeconomic evaluations:  
1. Cost minimization analysis (CMA): It involves comparing two or more 
treatment alternatives with the same outcome to determine the least 
costly alternative. 
2. Cost effectiveness analysis (CEA): It compares programme or 
treatment alternatives with different safety and efficacy profiles. 
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3. Cost utility analysis (CUA): It captures the impact of a therapy on the 
quality of life. It provides a method for estimating patient preference for 
a particular intervention in terms of the patient’s wellbeing. 
4. Cost benefit analysis (CBA): It allows the identification, measurement 
and comparison of the benefits and costs of programme/treatment 
alternatives by comparing the benefits from the treatment alternative 
with the costs of providing the same. 
4.6. Studies related to Drug utilization pattern of antihypertensive drugs: 
       A DUS of antihypertensive agents in essential hypertension done in 
Kathmandu, Nepal by Joshi et al.4 showed that CCBs are most commonly 
used followed by β-blockers, diuretics, ACE inhibitors and ARBs. Among two 
drug combinations, most commonly used combination was amlodipine with 
atenolol followed by amlodipine with diuretic, amlodipine with enalapril, 
atenolol with diuretic, atenolol with enalapril and atenolol with losartan. The 
highest prescribed combination of three drugs is amlodipine with atenolol 
and enalapril followed by the combination of amlodipine with atenolol and 
losartan. 
      A DUS of antihypertensive drugs done in Karolinska Institute, Huddinge, 
Sweden by Al-Windi et al.6 showed that β-blockers were most commonly 
used drugs followed by diuretics, ACE inhibitors and CCBs. 
       A DUS of antihypertensive drugs done in 20 private hospitals of 
Tanzania by Rimoy et al.7 showed that most frequently prescribed 
antihypertensive drug as monotherapy was atenolol followed by 
bendrofluazide, frusemide, hydralazine, nifedipine, amlodipine and enalapril. 
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Among the combination therapy ACE inhibitor with diuretic was commonly 
used followed by β-blocker with diuretic, CCB with losartan, β-blocker with 
ACE inhibitor, CCB with ACE inhibitor and diuretic with hydralazine. 
      A DUS conducted at Majeedia hospital, New Delhi by Khurshid et al.8 on 
antihypertensive drugs showed that majority of the subjects were on multiple 
drug therapy. Diuretics was the most frequently prescribed antihypertensive 
drug in overall utilization followed by β-blockers, CCBs, ACE inhibitors, 
ARBs and α1-blocker. Amlodipine was the most commonly prescribed 
antihypertensive drug followed by atenolol, ramipril and furosemide. Among 
the two drug combinations most commonly used is CCBs with β-blockers 
followed by ACE inhibitor with Diuretics. Among the three drug combinations 
ACE inhibitors with β-blockers and CCBs comprised the most commonly 
prescribed combination. 
      A DUS of antihypertensive drugs done in South Malabar region of Kerala 
by Augustine et al.29 showed that β-blockers are the most commonly 
prescribed drug group, followed by CCBs and diuretics. Atenolol, amlodipine 
and enalapril were the most frequently used β-blocker, CCB and ACE 
inhibitor respectively. Furosemide was the most commonly used diuretic. In 
FDC prescriptions majority were a combination of β-blocker and CCB 
followed by diuretic with either β-blocker or CCB or ACE inhibitor. The 
remaining FDCs were combinations of diuretics, ARB with ACE inhibitor or 
β-blocker. 
      A DUS by Beg et al.30 in Uttarakhand showed that ARBs were most 
commonly prescribed drugs followed by ACE inhibitors, β-blockers and 
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CCBs. Among ARBs, the frequently used drugs were olmesartan, losartan 
and telmisartan. Amongst ACE inhibitors the most commonly prescribed 
drug was ramipril followed by enalapril. Atenolol was the most commonly 
prescribed β-blocker followed by metoprolol and nebivolol. Amlodipine was 
the only CCB prescribed. Most commonly used two drug combinations are 
amlodipine with atenolol followed by olmesartan with hydrochlorothiazide, 
losartan with hydrochlorothiazide, ramipril with hydrochlorothiazide and 
telmisartan with hydrochlorthiazide. Three drug combination used was 
olmesartan with amlodipine and hydrochlorthiazide. 
      A study of prescription trends and rationality of antihypertensive drugs 
done in Government Medical College, Jammu and Kashmir, India among 
Indian postmenopausal women by Tandon et al.31 showed that as 
monotherapy ARBs are most commonly prescribed drugs followed by CCBs, 
ACE inhibitors, β-blockers and diuretics. Amlodipine among CCBs, 
telmisartan and losartan among ARBs, ramipril and enalapril among ACE 
inhibitor and atenolol and metoprolol among β-blockers were often 
prescribed. Among combination therapy ARB with diuretic was commonly 
used followed by CCBs with β-blocker. 
      An antihypertensive medication prescribing study by McAlister et al.32 in 
27,822 elderly Canadians with diabetes showed that ACE inhibitors, thiazide 
diuretics and CCBs were the commonly used antihypertensive medications. 
      A DUS by Liu et al.33 showed that among newly diagnosed cases of 
uncomplicated hypertension in Taiwan, CCBs are most frequently prescribed 
antihypertensive regimens followed by β-blockers, ACE inhibitors, CCBs with 
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β-blockers, diuretics, CCBs with ACE inhibitors, ARBs, CCBs with ARBs and 
β-blockers with diuretics. 
      A study of antihypertensive prescribing patterns for adolescents with 
primary hypertension done in Michigan by Yoon et al.34 showed that ACE 
inhibitor was the commonly prescribed drug as monotherapy followed by β-
blocker and diuretics. The 3 most commonly prescribed drug combinations 
were ACE inhibitor with diuretic, combination of two diuretics and β-blocker 
with diuretic combinations. 
      A study of antihypertensive medication use among elderly patients 
conducted in Dhanalakshni Srinivasan Medical college and hospital, 
Perambalur, Tamilnadu by Gupta et al.35 showed that CCBs were the most 
frequently used drugs followed by diuretics, β-blockers, ACE inhibitors and 
ARBs. 
      A DUS of antihypertensive drugs done in Coimbatore by Sakthi et al.36 
showed that among patients who were treated with monotherapy of 
antihypertensive drugs, CCBs was most commonly used followed by ACE 
inhibitors, ARBs and β-blockers. FDC used were ACE inhibitor combination 
with CCB and diuretics. The other major combination prescribed was β 
blockers with diuretics. 
      A DUS of antihypertensive drugs conducted in Nigeria by Kehinde et 
al.37 showed that for the initiation of therapies, diuretics were the most 
prescribed antihypertensives either as monotherapy or in combination with 
other agents followed by CCBs, ACE inhibitors, centrally acting agents, β-
blockers, ARBs and α-blockers. Among FDC amiloride with 
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hydrochlorothiazide was most frequently prescribed. In diuretics, thiazides 
are most frequently prescribed followed by the potassium sparing diuretics 
and loop diuretics. 
      A study of prescribing pattern of antihypertensive drugs done in 
Bangladesh by Sultana et al.38 showed that ACE inhibitors are most 
commonly used antihypertensive drugs followed by β-blockers, ARBs, 
diuretics and CCBs. 
      A descriptive, cross-sectional survey conducted in 22 primary healthcare 
facilities across Trinidad by Clement et al.39 showed that ACE inhibitors were 
the most commonly used class of antihypertensive drugs followed by β-
blockers, diuretics and CCBs. 
      A prospective, cross-sectional study conducted in the Cardiology and 
Medicine outpatient departments by Janaki et al.40 showed that out of 346 
prescriptions, 208 prescriptions were for the newly diagnosed cases of 
hypertension and in that 154 prescriptions contained monotherapy and 54 
prescriptions contained combined therapy. The most frequently prescribed 
antihypertensive drugs in these patients as monotherapy were atenolol, 
amlodipine, enalapril and metoprolol. Out of 54 prescriptions for the newly 
diagnosed cases of hypertension, 32 prescriptions contained a combination 
of atenolol with amlodipine and 22 prescriptions contained a combination of 
losartan with hydrochlorothiazide.  
      A DUS among hypertensive patients in a Sub-Urban hospital in Malaysia 
by Baig et al.41 showed that most of the patients were on treatment with 
polytherapy for hypertension while rest were treated with monotherapy. 
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Metoprolol were the most frequently prescribed drug followed by perindopril, 
amlodipine, atenolol, frusemide, captopril, felodipine, chlorthiazide, 
nifedipine, carvedilol, losartan, ramipril, terazosin and doxazosin. 
      In a  DUS of antihypertensive drugs in obstetric practice conducted in 
two tertiary care hospitals in Gulbarga city by Hooli et al.42 showed that in a 
total of 200 obstetric prescriptions studied, frequency of use of nifedipine 
was highest followed by benzathiazide with triamterene, amlodipine, 
furosemide, methyldopa and spiranolactone. The use of the safest drug, 
methyldopa was only in 4% of patients. 
      In an antihypertensive drug utilisation study in hospital Tengku Ampuan 
Afzan, Kuantan by Azarisman et al.43 showed that majority of patients were 
on either 2 or 3 antihypertensive drugs. The most frequently prescribed 
medications were ACE Inhibitors, CCBs, diuretics and β-blockers. 
     A study of prescribing pattern of antihypertensive drugs conducted in 
Department of Cardiology at Krishna Institute of Medical Sciences, 
Hyderabad by Arief et al.44 has showed that as monotherapy, ACE inhibitors 
were the most commonly prescribed antihypertensive drugs followed by 
CCBs and diuretics. Among combination therapy often 2 drug combinations 
were prescribed, the most common combination was ACE inhibitor with CCB 
followed by β-blocker with CCB. 
      An observational, non-interventional, prospective study conducted at 
Owaisi hospital and research centre, Kanchanbagh, Hyderabad by Ghori et 
al.45 showed that among the 400 hypertensive patients, 351 patients 
received monotherapy and only 49 patients received a combination therapy 
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of antihypertensive drugs. In patients receiving monotherapy, ACE inhibitors 
were most commonly used followed by CCBs, diuretics, β-blockers and 
ARB. Among all ACE inhibitors, ramipril was the most commonly prescribed. 
Among the CCBs the most commonly prescribed drugs were amlodipine and 
felodipine. Telmisartan was the most commonly prescribed ARB.  A two drug 
combination of CCB with ACE inhibitor were prescribed to a majority of 
patients, followed by a combination of β-blockers with CCB, ACE inhibitor 
with loop diuretics and combination of two CCBs. 
      A study of prescription pattern of antihypertensive drugs done in the 
cardiology department of St. John's Medical College Hospital, Bangalore by 
Xavier et al.46 showed that CCBs were most commonly prescribed, followed 
by ACE Inhibitors, β−blockers, diuretics, α-blockers and α2 central agonists. 
Amlodipine, enalapril, metaprolol, furosemide and clonidine are the 
commonly used drugs in their respective groups. 
      A study of antihypertensive drug utilization done in Department of 
Cardiology, National Institute of Cardiovascular Diseases, Dhaka by 
Majumder et al.47 showed that in less than 55 years old mild hypertensive 
patients, the most commonly used antihypertensive drugs are ACE inhibitor 
for males and CCB for females and in more than 55 years old mild 
hypertensive patients, most commonly used antihypertensive drugs are 
CCBs for both male and female patients. In less than 55 years old moderate 
hypertensive patients, the most commonly used antihypertensive drugs are 
ACE inhibitor for males and CCB for females and in more than 55 years old 
moderate hypertensive patients, the most commonly used antihypertensive 
drugs are CCBs for both male and female patients. In case of less than 55 
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years old severe hypertensive patients, the most commonly used 
antihypertensive drugs are combinations of ACE inhibitor with CCB and 
diuretic for both male and female patients and in more than 55 years old 
severe hypertensive patients, the most commonly used antihypertensive 
drugs are combinations of ACE inhibitor with CCB and diuretic for males and 
combinations of CCB with β-blocker for females.  
      A drug utilization study of antihypertensive drugs done in Germany by 
Pittrow et al.48 showed that the drug classes most frequently prescribed were 
ACE inhibitors followed by β-blockers, diuretics, CCBs, ARBs and α-
blockers. 
      A study of trends of physician prescriptions of the major antihypertensive 
classes among Chinese patients in primary care clinics in Hong Kong by 
Wong et al.49 showed that among all antihypertensive drugs, CCBs and β-
blockers were the most commonly prescribed drugs, followed by ACE 
inhibitor, α-blockers and thiazide diuretics. Among prescriptions of β blockers 
metoprolol and atenolol were commonly used while for CCBs, the 
commonest drug was nifedipine followed by diltiazem. The majority of 
patients were on monotherapy, followed by two class polytherapy. The most 
common prescription for two drug therapy consists of β-blocker with CCB 
polytherapy, followed by ACE inhibitor with CCB. 
      A DUS of antihypertensive drugs conducted in Palestine by Sweileh et 
al.50 showed that out of 574 antihypertensive prescriptions 309 were males 
and 265 females. 277 prescriptions were based on monotherapy while 297 
prescriptions were based on combination therapy. Of the monotherapy 
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prescriptions most commonly used was β-blockers, followed by ACE 
inhibitors, CCB, diuretics, ARBs, central sympatholytic and direct 
vasodilators. The most common two drug combination was β-blockers with 
diuretics followed by ACE inhibitor with diuretics, β-blockers with ACE 
inhibitor, ACE inhibitor with CCB, CCB with diuretics, ARBs with diuretics, β-
blockers with CCB, ARB with β-blockers. Among β-blockers, the drugs used 
were atenolol, propranolol and metoprolol. Among ACE inhibitors, the drugs 
used were enalapril, captopril, benzapril and ramipril. Among CCBs, the 
drugs commonly used were nifedipine and amlodipine. Among diuretics, the 
drugs used were hydrochlorothiazide, triamterene and furosemide. Among 
ARBs, the drugs used were valsartan, candesartan and losartan. 
      A DUS of antihypertensives conducted at JJM Medical College Hospital, 
Davangere by Sagar et al.51 shows that among 210 prescriptions, 126 
prescriptions were of patients with hypertension alone which contain mainly 
CCBs followed by β blockers, ARBs, ACE inhibitors and FDCs of ARBs with 
hydrochlorothiazide and combination of amlodipine with hydrochlorothiazide. 
Eighty four prescriptions of hypertension with coexisting diabetes mellitus 
had mainly CCBs, ACE inhibitors, ARBs, β-blockers, and FDCs of ARBs with 
hydrochlorothiazide and combination of amlodipine with hydrochlorothiazide. 
      A retrospective, cross-sectional study of antihypertensive prescriptions of 
hypertensive patients admitted in Medicine inpatient wards of Kasturba 
Medical College Hospital, Attavar, Mangalore by Pai et al.52 showed that 
majority of the patients received multiple drug therapy. CCBs were the most 
commonly prescribed drugs followed by diuretics, ACE inhibitors, β-blockers, 
ARBs, α-blockers and central sympatholytics, the leading drugs being 
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amlodipine, hydrochlorothiazide, enalapril, atenolol, losartan, prazosin and 
clonidine in the respective groups. Among those who were treated with drug 
combinations, 67.7% received two drugs, 27.5% received a regimen of three 
drugs and 4.9% received a combination of four drugs. The ARB with diuretic 
was the most frequently prescribed followed by a combination of two 
diuretics and CCBs with β-blockers. The most commonly prescribed FDCs 
among combination regimens were diuretics with ARBs.  
      A Prescription pattern study of antihypertensive drugs done in 
S.Nijalingappa Medical College, Bagalkot, Karnataka by Kale et al.53 showed 
that CCBs were the most commonly prescribed drugs followed by diuretics, 
ACE inhibitors, β-blockers, ARBs, α-blockers and central sympatholytics, the 
leading drugs being amlodipine, hydrochlorothiazide, enalapril, atenolol, 
losartan, prazosin and clonidine in the respective groups.  
      In a DUS of antihypertensive agents conducted at the Panjab University 
Health Centre in India by Tiwari et al.54 showed that more number of patients 
were treated with a single antihypertensive drug when compared to patients 
treated with antihypertensive drug combinations. Among those who were 
treated with two drug antihypertensive combinations a β-blocker with a CCB 
was commonly used followed by a β-blocker with a diuretic, a β-blocker with 
an ACE inhibitor, and a diuretic with a CCB. Among the monotherapy 
category, CCBs were commonly used followed by β-blockers, ACE inhibitors 
and diuretics. 
      A cross-sectional observational study of prescription pattern of 
antihypertensive drugs done in the outpatient department of Shri Sathya Sai 
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Medical College and Research Institute, Chennai by Maduram et al.55 has 
shown that the highly prescribed single drug was amlodipine followed by 
enalapril, atenolol, verapamil, propranolol and metoprolol. The highly 
prescribed combinations of drug were amlodipine with enalapril followed by 
amlodipine with atenolol, amlodipine with furosemide, enalapril with 
furosemide, enalapril with atenolol, enalapril with verapamil, amlodipine with 
propranolol and amlodipine with metoprolol. The drugs prescribed in three 
drugs combinations were amlodipine, enalapril and atenolol or nifedipine or 
furosemide or metoprolol and the other combination of atenolol and 
furosemide, enalapril or metoprolol. The patients with asthma and DM were 
commonly prescribed either enalapril or amlodipine. 
      A prescription pattern study of antihypertensive drugs conducted in 
General medicine department at Sri Muthukumaran Medical college Hospital 
and Research Institute, Chikarayapuram, Chennai by Janagan et al.56 has 
shown that patients receiving combination antihypertensive agents were 
more than those receiving monotherapy. In patients receiving monotherapy, 
ACE inhibitors were commonly prescribed class followed by ARBs, 
cardioselective β-blockers, CCBs and diuretics. In combination therapy, ACE 
inhibitors with thiazide diuretics are the most commonly prescribed 
combination followed by ARBs with thiazide diuretics, ACE inhibitors with 
CCBs and ARBs with β blockers. The three drug regimen used was ACE 
inhibitor with thiazide diuretic and β blockers. 
      A DUS of antihypertensive drugs conducted in Chandigarh by Dhanaraj 
et al.57 showed that majority of the patients were on combination therapy 
followed by monotherapy. Among the patients on combination therapy two 
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drug combination was commonly preferred followed by three and four drug 
combination therapy. Patients on monotherapy were mostly receiving ACE 
inhibitors and ARBs followed by β-blockers. In two drugs combination 
therapy, ACE inhibitors with ARBs or diuretics were commonly used followed 
by ARBs with diuretics, ACE inhibitors with CCBs, and ARB with CCBs. In 
three drug combinations, combination of ACE inhibitors with ARB and 
diuretics were highest followed by ARB with CCB and diuretics. In 4 or more 
drug combinations of ARB, ACE inhibitor, CCBs with diuretics were 
commonly prescribed.  
      A DUS of antihypertensive drugs conducted in Jordan by Al-Drabah et 
al.58 showed that majority of the patients were on monotherapy of 
antihypertensive drugs followed by two drug, three drug and four drug 
combination therapy. Among patients receiving monotherapy ACE inhibitors 
was most commonly used followed by β-blockers, CCBs, ARBs and 
diuretics. Among patients on two drug combination therapy most commonly 
used combination was a diuretic with a β-blocker followed by an ACE 
inhibitor with a β-blocker. In patients on three drug combination therapy 
diuretic with a β-blocker and ARB was commonly used. Patients on four drug 
combination therapy the most frequently used combinations included a 
diuretic, an ACE inhibitor, a β-blocker and a CCB. 
      A drug utilization study of hypertensive patients conducted in Punjab by 
Bajaj et al.59 showed that diuretics was the most commonly prescribed group 
of antihypertensive drugs followed by ARBs, β-blockers and CCBs. Out of 
diuretics, thiazides group was the most commonly used. Majority of the 
patients were on combination therapy. 
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      A DUS of antihypertensive drugs conducted at Warangal, India by 
Pavani et al.60 revealed that majority of the patients were on two drug 
combination therapy followed monotherapy and triple therapy. In multiple 
drug therapy, maximum number of patients were prescribed with FDCs. 
Among patients who underwent monotherapy majority of the patients were 
prescribed with ARBs followed by CCBs, ACE inhibitors, diuretics and β-
blockers. Among patients in whom two antihypertensives were prescribed, 
majority of the patients were prescribed with a combination of diuretics and 
ARBs followed by diuretics and ACE inhibitors and diuretics and β-blockers. 
Results of the triple therapy revealed that, maximum number of the patients 
were prescribed with diuretics along with ARBs and β-blockers, followed by 
diuretics with ARBs and ACE inhibitors and diuretics with ARBs and CCBs.  
      A DUS of antihypertensive drugs done in Vadodara, India by Shah et 
al.61 showed that majority of hypertensive patients were on monotherapy 
followed by two and three drug combination therapy. Patients on 
monotherapy mostly received ACE inhibitor or ARB followed by β-blockers, 
CCBs, thiazide diuretics and combined α and β blockers. Most common 
prescribed combinations were amlodipine with atenolol, losartan with 
hydrochlorthiazide and metoprolol with amlodipine. Most commonly used 
multi drug combination therapy was CCB with β-blocker followed by ARB 
with diuretic, CCB with diuretic, ARB with CCB and ARB with diuretic and 
combined α and β blocker. 
      A DUS of antihypertensive drugs conducted in Andhra Pradesh by 
Sindhu et al.62 majority of hypertensive patients were on two drug 
combination therapy followed by monotherapy and patients on three drug 
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combination therapy. In that most of the drug prescriptions were as FDCs. 
CCBs were the commonly prescribed drugs as monotherapy followed by 
ARBs, ACE inhibitors, β-blockers and diuretics. Among patients on two drug 
combination therapy ARBs with diuretics were the mostly prescribed 
combination followed by β-blocker with CCBs. Diuretics with ARBs and 
CCBs was the commonly prescribed three drug combination.  
      A drug utilization study of antihypertensive drugs conducted at Deccan 
College of Medical Sciences, Hyderabad by Sandozi et al.63 was conducted 
as 2 phases between 2008 and 2009-10. Out of 300 cases recorded in 
Phase 1, 47% were men and 53% were women. Majority of the patients 
were on monotherapy of antihypertensive drugs. The most commonly 
prescribed drug was CCB, amlodipine followed by β-blockers atenolol and 
metaprolol, ACE inhibitors, diuretics and ARBs. 84 out of 300 patients had 
associated DM. In that most of the patients were on monotherapy of ACE 
inhibitors followed by β-blockers, CCBs and ARBs. Commonly used 
combination was ACE inhibitors with diuretics. Out of 450 patients recorded 
in phase 2, majority of the patients were men. 105 of these were having DM. 
Most of the patients were on monotherapy and most prescribed drugs were 
ACE inhibitors followed by CCBs, β-blockers, ARBs and diuretics. 
Commonly used combinations were β-blockers with CCBs, ACE inhibitors 
with diuretics and ARBs with diuretics.  
      A prescription pattern study of antihypertensive drugs conducted at 
Indirapuram, Ghaziabad (U.P) by Bhardwaj et al.64 showed that ARBs and 
diuretics were the most commonly prescribed drugs followed by β-blockers, 
CCBs and ACE inhibitors. Among the 37 patients prescription, majority was 
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prescribed as monotherapy and some as combination therapy. Most 
commonly prescribed drug in monotherapy were amlodipine, telmisartan and 
indapamide and nebivolol, losartan and olmesartan were least prescribed. 
Most commonly prescribed drug in combination therapy was 
hydrochlorthiazide and telmisartan.  
      A DUS of antihypertensive drugs conducted in South India by John et 
al.65 showed that among the antihypertensive drugs prescribed CCBs, β-
blockers and ACE inhibitors represented the major classes. CCBs 
(amlodipine) were the most widely used antihypertensive followed by β-
blockers. Amlodipine was the single most commonly prescribed 
antihypertensive drug followed by metoprolol. 
      A DUS of antihypertensive drugs conducted by Fretheim et al.66 showed 
that CCBs and ACE inhibitors were the most commonly used drugs for the 
treatment of hypertension. 
4.7. Studies related to Pharmacovigilance of antihypertensive drugs: 
      A study of ADRs due to antihypertensive drugs conducted in Majeedia 
Hospital at Hamdard University Campus in New Delhi by Hussain et al.67 
ADRs were more common in females than males. The most vulnerable age 
group was 41–50 years with respect to ADRs followed by 51-60 years, 61-70 
years, 31-40 years, >70 years and 20-30 years. More ADRs were reported in 
patients receiving combination therapy when compared to patients on 
monotherapy. Among the systems affected, ADRs commonly affected 
cardiovascular system followed by gastrointestinal system and respiratory 
system. On WHO scale of causality assessment most of the ADRs were 
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possible followed by probable and unlikely. Commonly experienced ADRs in 
the patients on β-blockers was hypotension, headache, giddiness and 
bradycardia in patients on atenolol and bronchospasm, impotence, and 
irritation over whole body seen in patients on metoprolol and pedal edema 
with nebivolol. Dry cough was the only ADR observed with ACE inhibitors 
mainly due to enalapril and ramipril. ADRs experienced with the use of CCBs 
were pedal oedema, swelling of the face, generalised oedema, headache, 
and giddiness with the use of amlodipine and bradycardia with the use of 
nifidipine. In this study it was found that β-blockers were most frequently 
associated with ADRs followed by ACE inhibitors and CCBs. 
      A study of ADRs due to antihypertensive drugs conducted in New Delhi 
by Khurshid et al.10 showed that out of 192 patients, 13 developed ADRs. 
Prevalence of ADRs due to antihypertensive drugs was found to be more 
infemales. The most vulnerable age group was 41–50 years with respect to 
ADRs followed by 71–80 years, 51–60 years, 31–40 years and 61–70 years. 
CCBs were commonly associated with ADRs followed by diuretics, β-
blockers, ARBs and ACE inhibitors. Among individual drugs amlodipine was 
frequently ADRs followed by torasemide and ramipril. The common ADRs 
seen with the use of amlodipine were abdominal pain, pedal oedema, 
drowsiness and back pain. Common complaints with torasemide were 
fatigue, visual impairment and dizziness. Dry cough was the most frequent 
ADR observed with ramipril. Naranjo’s probability scale showed that most of 
the ADRs were possible followed by probable and a few as unlikely. ADRs 
associated with central nervous system were most common followed by 
musculo-skeletal complaints and gastrointestinal disorders. 
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      A study of ADRs associated with the use of antihypertensive drugs 
conducted in Gujarat, India by Joshi et al.68 showed that all hypertensive 
drugs caused dizziness, ankle swelling, headache, fatigue, chest discomfort 
and cough. Erectile dysfunction was the adverse effect of thiazide diuretics. 
Severe hypotension occurred after initial doses of any ACE inhibitor. 
Infrequent ADRs were associated with ARBs which included first dose 
orthostatic hypotension, diarrhea, rash and dyspepsia. ADRs associated 
with the use of β-blockers included nausea, bronchospasm, diarrhea, 
dyspnea and cold extremities. The most common side effects caused by the 
CCBs included dizziness, headache, hypotension, flushing, digital 
dysesthesia and nausea. 
      A study of ADRs due to antihypertensive drugs done in outpatient 
department of rural medical hospital in Loni, India by Kale et al.69 showed 
that common adverse drug reactions were dry cough, weakness, headache, 
mild dizziness, dryness of mouth and ankle swelling. 
      A study of ADRs due to antihypertensive drugs done in BRD Medical 
College, Gorakhpur, India by Upadhayai et al.70 showed that out of 1147 
patients who were on antihypertensive drugs 54 patients developed skin 
reactions. Maximum number of patients with adverse cutaneous drug 
reactions (ACDR) was seen with atenolol followed by amlodipine. The most 
common type of ACDR was urticaria followed by lichenoid drug eruption. 
      A study of ADRs in hypertensive patients in a primary care setting done 
in Mexican Institute of Social Security, Mexico by Mino-Leon et al.71 has 
shown that ADRs seen with the use of captopril are somnolence, cough, 
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dizziness, headache, anxiety and fatigue. ADRs with enalapril are cough and 
paresthesia. ADRs seen with the use of metoprolol are confusion, 
nervousness and somnolence. Headache and fatigue were seen in patients 
on verapamil. Nifedipine caused dizziness, headache and paresthesia. 
      A study of ADRs due to antihypertensive drugs conducted at Jordan by 
Al-Drabah et al.58 showed that the most frequent ADRs related to the use of 
antihypertensive drugs were postural hypotension followed by lower limb 
edema and palpitations. 
      A retrospective evaluation of ADRs at Pugliese-Ciaccio Hospital of 
Catanzaro, Italy by Rende et al.72 has shown that common ADRs recorded 
in patients taking antihypertensive drugs are hypotension, hyponatremia, 
cough, hyperkalemia, hypokalemia and swollen foots. 
      A study of ADRs due to antihypertensive drugs conducted in Warangal, 
Andhra Pradesh by Sindhu et al.62 showed that among 205 patients 
recruited 85 patients reported to have adverse effects. Commonest ADR 
was dizziness, followed by nausea, edema and dry cough. 
      A study of ADRs due to antihypertensive drugs carried out in medical 
ICU of hospital in South India by John et al.65 showed that the commonly 
encountered ADRs to the antihypertensive drugs were dyselectrolytemia by 
enalapril and drug induced bradycardia by metoprolol. 
      An ADR monitoring study of telmisartan in hypertensive patients 
conducted in Maharashtra by Suhas et al.73 has shown that headache, 
respiratory infection, giddiness, pain, weakness, gastrointestinal tract 
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problems, sinusitis, pharyngitis, indigestion, muscle pain, cough and urinary 
tract infection as the common ADRs. 
      An ADR monitoring study of antihypertensive drugs conducted in UAE by 
Alomar et al.74 has reported that ADRs during the study were headache, 
giddiness and ankle oedema, breathlessness, gastrointestinal tract problems 
and muscle pain. 
      A study of evaluation of the relative incidence of ADRs leading to 
treatment discontinuation of recommended antihypertensive drugs carried 
out at the cardiology unit of the Department of Medicine, University of 
Maiduguri teaching hospital, Nigeria by Ibn et al.75 has shown that cough 
was the reason cited for discontinuation of ACE inhibitors, peripheral 
oedema was seen with CCBs and bradycardia was seen with β-blockers. 
Diuretics showed the lowest discontinuation rate mainly due to hypokalemia. 
      A study of ADRs to antihypertensive drugs done in Raja Muthiah medical 
college, Annamalai University, Chidambaram, Tamilnadu by Basak et al.76 
reported that CCB as most common antihypertensive drug group 
responsible for ADR followed by ACE inhibitors and β-blockers. The ADRs to 
CCBs observed were dizziness, fatigue, dyspepsia and headache. ADRs to 
ARBs were dizziness and tachycardia. Huperuricemia, hypokalemia and 
muscle cramp was seen with the use of diuretics. ADRs seen with the use of 
ACE inhibitors were dry cough, headache and vomiting.  
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5. Materials and methods: 
5.1. Study design: 
      This study was a cross sectional study. 
5.2. Study setting: 
      This study was conducted at Department of General Medicine, Sree 
Mookambika Institute of Medical Sciences, Kulasekharam, Kanyakumari 
district, Tamilnadu. 
5.3. Time of the study: 
      This study was done over a period of 6 months during the time period of 
October 2013 and March 2014. 
5.4. Inclusion criteria: 
i. Patients receiving antihypertensive drugs from Medicine Department 
from October 2013 to March 2014 
ii. Patients of all age groups and both sexes  
5.5. Exclusion criteria: 
i. Patients already recruited in the study coming for refill of   
antihypertensive drugs 
5.6. Institutional Human Ethics Committee (IHEC) Approval: 
      The study proposal was approved by the Institutional Human Ethics 
Committee (IHEC) of SMIMS with Ref. No. SMIMS/IHEC/2013/A/22. The 
certificate of approval for the same has been enclosed in the annexure. 
5.7. Procedure: 
      The study was carried out in Medicine department of SMIMS, after 
getting approval from the Institutional Research Committee (IRC) and 
Institutional Human Ethics Committee (IHEC). Patients visiting the Medicine 
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depertment of the institution was included in this study after satisfying the 
inclusion and exclusion criteria, they were explained in detail about the study 
and informed written consent was obtained from each patient before 
recruiting them into the study. Details of prescribed antihypertensive drugs 
like formulation, whether  drug is prescribed using brand name or generic 
name, dose, route of administration, drugs taken before or after food, 
frequency, duration of the treatment, any adverse drug reactions, cost of 
drugs prescribed, any other co-morbid conditions and any other associated 
medications taken concurrently were recorded in the case record form. 
5.8. Data analysis and Presentation: 
A. Data obtained from case record form is presented as 
i. Number of patients receiving antihypertensive drug as monotherapy 
ii. Number of patients receiving antihypertensive drugs as combination 
therapy 
iii. Number of patients receiving different classes of antihypertensive 
drugs like thiazide diuretics, ACE inhibitors, CCBs, α and β blockers, 
ARBs, vasodilators etc. 
iv. Number of prescriptions of antihypertensive drugs by generic and 
brand names. 
B. Cost of antihypertensive drugs which will be more economically viable and 
which will be more expensive for the patient. 
C. Number of patients who experienced different ADRs for different classes 
of antihypertensive drugs. 
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D. Casuality assessment of ADRs reported in patients prescribed with 
antihypertensive drugs by using WHO-UMC causality assessment scale 
and Naranjo scale. 
i. WHO-UMC system for causality assessment26: 
Certain: 
 Event or laboratory test abnormality, with plausible time 
relationship to drug intake 
 Cannot be explained by disease or other drugs 
 Response to withdrawal plausible 
 Event definitive pharmacologically or phenomenologically 
 Rechallenge satisfactory, if necessary 
Probable/ Likely: 
 Event or laboratory test abnormality, with reasonable time 
relationship to drug intake 
 Unlikely to be attributed to disease or other drugs 
 Response to withdrawal clinically reasonable 
 Rechallenge not required 
Possible:  
 Event or laboratory test abnormality, with reasonable time 
relationship to drug intake 
 Could also be explained by disease or other drugs 
 Information on drug withdrawal may be lacking or unclear 
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Unlikely:  
 Event or laboratory test abnormality, with a time to drug intake that 
makes a relationship improbable 
 Disease or other drugs provide plausible explanations 
Conditional/ Unclassified: 
 Event or laboratory test abnormality 
 More data for proper assessment needed, or 
 Additional data under examination 
Unassessable/ Unclassifiable: 
 Report suggesting an adverse reaction 
 Cannot be judged because information is insufficient or contradictory 
 Data cannot be supplemented or verified 
ii. Naranjo Causality Scale26: 
a. Are there previous conclusive reports on this reaction? 
Yes (+1), No (0), Do not know or not done (0) 
b. Did the adverse event appear after the suspected drug was given? 
Yes (+2), No (-1), Do not know or not done (0) 
c. Did the adverse reaction improve when the drug was discontinued 
or a specific antagonist was given? 
Yes (+1), No (0), Do not know or not done (0) 
d. Did the adverse reaction appear when the drug was readministered? 
Yes (+2), No (-1), Do not know or not done (0) 
e. Are there alternative causes that could have caused the reaction? 
Yes (-1), No (+2), Do not know or not done (0) 
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f. Did the reaction reappear when a placebo was given? 
Yes (-1), No (+1), Do not know or not done (0) 
g. Was the drug detected in any body fluid in toxic concentrations? 
Yes (+1), No (0), Do not know or not done (0) 
h. Was the reaction more severe when the dose was increased, or less 
severe when the dose was decreased? 
Yes (+1), No (0), Do not know or not done (0) 
i. Did the patient have a similar reaction to the same or similar drugs 
in any previous exposure? 
Yes (+1), No (0), Do not know or not done (0) 
Scoring 
 > 9 = definite ADR 
 5-8 = probable ADR 
 1-4 = possible ADR 
 0 = doubtful ADR 
E. Severity assessment of ADRs due to antihypertensive drugs by Hartwig 
severity scale.28 
Mild: 
Level 1: The ADR requires no change in treatment with the suspected 
drug. OR 
Level 2: The ADR requires that the suspected drug be withheld, 
discontinued or otherwise changed. No antidote or other treatment is 
required and there is no increase in length of stay. 
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Moderate: 
Level 3: The ADR requires that the suspected drug be withheld, 
discontinued or otherwise changed, and/ or an antidote or other 
treatment is required. There is no increase in length of stay. OR 
Level 4 (a): Any level 3 ADR that increases length of stay by at least one 
day. OR 
Level 4 (b): The ADR is the reason for admission. 
Severe: 
Level 5: Any level 4 ADR that requires intensive medical care. OR 
Level 6: The ADR causes permanent harm to the patient. OR 
Level 7: The ADR either directly or indirectly leads to the death of the 
patient. 
F. Preventability criteria of ADRs due to antihypertensive drugs by 
Schumock and Thornton scale.27 
Definitely Preventable: 
1. Was there a history of allergy or previous reactions to the drug? 
2. Was the drug involved inappropriate for the patient’s clinical 
condition? 
3. Was the dose, route or frequency of administration inappropriate for 
the patient’s age, weight or disease state? 
4. Was a toxic serum drug concentration (or laboratory monitoring test) 
documented? 
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5. Was there a known treatment for the ADR? 
Probably Preventable: 
6. Was required Therapeutic drug monitoring or other necessary 
laboratory tests not performed? 
7. Was a drug interaction involved in the ADR? 
8. Was poor compliance involved in the ADR? 
9. Were preventative measures not prescribed or administered to the 
patient? 
Not preventable: 
      If all above criteria not fulfilled 
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6. Results: 
      The present cross-sectional study of drug utilization pattern and adverse 
drug reaction profile of antihypertensive drugs was done at the Department of 
Medicine, Sree Mookambika Institute of Medical Sciences, Kulasekharam, 
Tamilnadu, for a period of 6 months (from October 2013 to March 2014). Total 
of 127 prescriptions and 86 ADRs were collected and analysed. In this study 
it was noted that in all prescriptions lifestyle modifications were recommended 
for all patients with hypertension irrespective of antihypertensive drug therapy. 
In all the prescriptions recorded, the route of administration of 
antihypertensive drugs was oral. 
6.1. Age distribution of patients studied: 
      In the current study out of 127 patients, 65 patients (51.18%) belonged to 
age group of 61-70 years. There were 34 patients (26.77%) in age group of 
51-60 years, 16 patients (12.6%) in age group of 71-80 years, 10 patients 
(7.87%) in age group of 41-50 years and 2 patients (1.58%) in age group of 
81-90 years as shown in Table 1. 
6.2. Gender distribution of patients studied: 
      In the current study out of 127 patients, 32 (25.2%) were male and 95 
(74.8%) were female as shown in Table 1.  
6.3. Body mass index of patients studied:      
      Calculation of body mass index showed that out of 127 patients, 73 
(57.48%) were of normal weight, 44 (34.65%) were overweight and 10 
(7.87%) were underweight as shown in Table 1. 
  Results 
77 | P a g e  
 
6.4. Socioeconomic status of patients studied: 
      Socioeconomic status of the patients studied were grouped as per their 
monthly per capita income according to modified Prasad classification 2013.77 
Out of 127 patients, 67 (52.76%) belonged to class III. Number of patients in 
other classes were 34 (26.77%) in class IV, 11 (8.66%) in class II, 8 (6.3%) in 
class V and 7 (5.51%) in class I as shown in Table 2. 
6.5. Co-morbid conditions: 
      In the current study, out of 127 patients, 84 had co-morbid conditions. Out 
these 84 patients, 33 (39.28%) were suffering from concurrent diabetes 
mellitus. Other associated co-morbid conditions were COPD in 22 patients 
(26.19%), DM with COPD in 11 patients (13.1%), CAD in 11 patients (13.1%), 
Dyslipidaemia in 3 patients (3.57%), CVA in 2 patients (2.38%), Mitral stenosis 
in 1 patient (1.19%) and Hypothyroidism in 1 patient (1.19%) as shown in 
Table 2. 
6.6. Drugs prescribed by generic and brand name: 
      In the present study, in all the 127 prescriptions, all the antihypertensive 
drugs were prescribed by brand name as shown in Figure 1. 
6.7. Number of patients receiving monotherapy or combination drug 
therapy of antihypertensive drugs: 
      In the current study, there were total 127 prescriptions of antihypertensive 
drugs. Among 127 prescriptions, 96 (75.59%) were monotherapy and 31 
(24.41%) were combination therapy. Among the prescriptions of 
antihypertensive drugs as combination therapy 22 (17.32%), 7 (5.51%) and 2 
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(1.58%) were combination of two, three and four drugs respectively. The 
details of patients receiving monotherapy or combination drug therapy has 
been depicted in Figure 2. 
6.8. Number of patients receiving monotherapy of antihypertensive 
drugs: 
      In present study 96 (75.59%) patients had received single drug for the 
treatment of hypertension. Amlodipine was the most commonly used drug 
which was prescribed for 84 (87.5%) patients. Other drugs prescribed as 
monotherapy were ramipril for 3 (3.14%) patients, nifedipine for 2 (2.08%) 
patients, telmisartan for 2 (2.08%) patients, metoprolol for 2 (2.08%) patients, 
losartan for 1 (1.04%) patient, nebivolol for 1 (1.04%) patient and furosemide 
for 1 (1.04%) patient as shown in Figure 3. 
6.9. Number of patients receiving two drug combination therapy of 
antihypertensive drugs: 
      Out of 127 patients two drugs were prescribed for 22 (17.32%) patients. 
Amlodipine + atenolol was most commonly prescribed two drug combination 
which was prescribed for 6 patients (27.26%). Other two drug combinations 
prescribed were amlodipine + furosemide for 5 patients (22.72%), telmisartan 
+ hydrochlorothiazide for 3 patients (13.63%), amlodipine + ramipril for 2 
patients (9.09%), enalapril + hydrochlorothiazide for 1 patient (4.55%), 
amlodipine + losartan for 1 patient (4.55%), telmisartan + amlodipine for 1 
patient (4.55%), losartan + hydrochlorothiazide for 1 patient (4.55%), 
carvedilol + ramipril for 1 patient (4.55%) and amlodipine + nebivolol for 1 
patient (4.55%) as shown in Figure 4. 
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6.10. Number of patients receiving three drug therapy of antihypertensive 
drugs: 
      Out of 127 prescriptions three drugs were prescribed for 7 (5.51%) 
patients. In that losartan + hydrochlorothiazide + amlodipine was the most 
commonly prescribed three drug combination prescribed for 3 patients 
(42.84%). Other three drug combinations prescribed were ramipril + 
amlodipine + atenolol for 1 patient (14.29%), amlodipine + atenolol + 
furosemide for 1 patient (14.29%), bisoprolol + ramipril + furosemide for 1 
patient (14.29%) and telmisartan + amlodipine + hydrochlorothiazide for 1 
patient (14.29%) as shown in Figure 5. 
6.11. Number of patients receiving four drug therapy of antihypertensive 
drugs: 
      The four drug combinations were the least prescribed. Four drugs were 
prescribed only for 2 (1.58%) patients. Telmisartan + hydrochlorothiazide + 
amlodipine + atenolol and telmisartan + hydrochlorothiazide + amlodipine + 
metoprolol were the two four drug combinations prescribed for 2 patients as 
shown in Figure 6. 
6.12. Expenditure of medications prescribed:       
      In present study at each visit antihypertensive drugs were prescribed for 
a period of one month. Metoprolol was the most expensive and furosemide 
was the least expensive drug prescribed as monotherapy. Telmisartan + 
hydrochlorothiazide + amlodipine was the most expensive and amlodipine + 
furosemide was the least expensive drug prescribed as combination therapy. 
Of all the brands of antihypertensive drugs prescribed, the cheapest was Lasix 
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(furosemide) for which the expenditure per month was INR 6.36 and the most 
expensive was the three drug combination of Telma H + Avacard (telmisartan 
+ hydrochlorothiazide + amlodipine) for which the expenditure per month was 
INR 524.82 as shown in figure 7, 8 and 9. 
6.13. Adverse drug reactions recorded: 
      In present study it has been observed that 86 ADRs developed for different 
types of antihypertensive drugs during the period of six months from October 
2013 to March 2014.  
6.14. Gender distribution of patients developing ADRs to antihypertensive 
drugs: 
      Among 86 patients who showed ADRs to antihypertensive drugs, 55 
(63.95%) were female and 31 (36.05%) were male as shown in Figure 10. 
6.15. Age distribution of patients developing ADRs to antihypertensive 
drugs: 
      ADRs to antihypertensive drugs were observed most commonly in age 
group of 61–70 years (n = 40, 46.51%). Other age groups affected were 51–
60 years (n = 24, 27.91%), 71–80 years (n = 13, 15.12%) and 41–50 years (n 
= 9, 10.46%) as shown in Figure 11. 
6.16. Number of patients on monotherapy and combination therapy 
developing ADRs shown with antihypertensive drugs: 
      Out of 86 patients who developed ADRs while receiving antihypertensive 
therapy, 36 (41.86%) were receiving monotherapy and 50 (58.14%) were 
receiving combination therapy as shown in Figure 12. 
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6.17. ADRs shown on treatment with different classes of antihypertensive 
drugs: 
      CCBs were found to be the commonest therapeutic class of 
antihypertensive drugs associated with ADRs (n = 54, 62.79%). Other groups 
associated with ADRs were ARBs (n = 11, 12.79%), β-blockers (n = 10, 
11.63%), ACE inhibitors (n = 6, 6.98%) and diuretics (n = 5, 5.81%) as shown 
in Figure 13. Among individual drugs amlodipine was found to be the 
commonest drug associated with ADRs (n = 41).  
6.18. ADRs to antihypertensive drugs affecting various systems: 
      In present study ADRs to antihypertensive drugs associated with central 
nervous system (n = 37, 43.03%) were found to be the most frequent 
[headache, dizziness, sedation and giddiness]. Other systems associated with 
ADRs were musculo-skeletal system (n = 25, 29.07%) [pedal edema, fatigue 
and muscle cramp], respiratory system (n = 11, 12.79%) [dry cough and 
breathlessness], gastrointestinal system (n = 8, 9.3%) [abdominal pain and 
diarrhoea], cardiovascular system (n = 4, 4.65%) [bradycardia] and skin (n = 
1, 1.16%) [irritation all over the body] as shown in Figure 14. 
6.19. WHO causality assessment scale: 
    According to WHO causality assessment scale most of the ADRs were 
“probable” 44 (51.16%), followed by “possible” 28 (32.56%), unclassifiable 10 
(11.63%) and unlikely 4 (4.65%) as shown in Figure 15. 
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6.20. Naranjo scale:  
      According to Naranjo scale 67 (77.91%) ADRs were “Possible”, 19 
(22.09%) were “Probable” and none were “Definite” as shown in Figure 16. 
6.21. Hartwig and Siegel severity assessment scale: 
      According to Hartwig and Siegel severity assessment scale 87.21% ADRs 
(n = 75) were “mild”, 12.79% ADRs (n = 11) were “moderate” and none of the 
ADRs were “severe” as shown in Figure 17. 
6.22. Modified Schumock and Thornton preventability scale: 
      According to Modified Schumock and Thornton preventability scale 
33.72% (n = 29) ADRs were “Definitely preventable” while 66.28% (n = 57) 
ADRs were “Probably preventable” and none of the ADRs were “Not 
preventable” as shown in Figure 18. 
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Table 1: Demographic profile of the patients studied  
Sl. No.   
1. Age in years Number of patients 
i.  41 - 50 10 
ii.  51 - 60 34 
iii.  61 - 70 65 
iv.  71 - 80 16 
v.  81 - 90 2 
2. Sex  
i.  Male 95 
ii.  Female 32 
3. Body mass index in Kg/m2  
i.  Normal weight 
(18.5 – 24.9) 
73 
ii.  Overweight (25 – 29.9) 44 
iii.  Underweight (<18.5) 10 
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Table 2: Socioeconomic status and comorbid conditions of the patients 
studied 
Sl. No.   
1. Socioeconomic status 
(Prasad classification) 
Number of patients 
i.  Class I 7 
ii.  Class II 11 
iii.  Class III 67 
iv.  Class IV 34 
v.  Class V 8 
2. Comorbid conditions  
i.  DM 33 
ii.  COPD 22 
iii.  DM + COPD 11 
iv.  CAD 11 
v.  Dyslipidaemia 3 
vi.  CVA 2 
vii.  Hypothyroidism 1 
viii.  Mitral stenosis 1 
 
 
 
 
 
 
DM :Diabetes Mellitus 
COPD :Chronic Obstructive Pulmonary Disease 
CAD :Coronary Artery Disease 
CVA :Cerebral Vascular Accident 
 
Prasad classification 201377 
Class I :Rs 5156 and above* 
Class II :Rs 2578 – 5155* 
Class III :Rs 1547 – 2577* 
Class IV :Rs 773 – 1546* 
Class V :Below Rs 773* 
*Per capita monthly income 
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Figure 1. Bar diagram showing the number of prescriptions of 
antihypertensive drugs by generic and brand names 
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Figure 2. Pie diagram showing the percentage of prescriptions of 
antihypertensive drugs as monotherapy and combination therapy 
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Figure 3. Bar diagram showing the number of prescriptions of 
antihypertensive drugs as monotherapy 
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Figure 4. Bar diagram showing the number of prescriptions of 
antihypertensive drugs as two drug combination therapy 
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Figure 5. Bar diagram showing the number of prescriptions of 
antihypertensive drugs as three drug combination therapy 
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Figure 6. Bar diagram showing number of prescriptions of 
antihypertensive drugs as four drug combination therapy 
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Brands of antihypertensive drugs prescribed as monotherapy
Avacard : Amlodipine 5 mg OD 
Starpress XL : Metoprolol 50 mg OD 
Ramitorva : Ramipril 5 mg + Atorvastatin 10 mg + Aspirin 75 mg OD 
Nicardia R : Nifedipine 20 mg OD 
Nebistar : Nebivolol 2.5 mg OD 
Telmikind : Telmisartan 40 mg OD 
Lasix : Furosemide 20 mg OD 
Losium : Losartan 50 mg OD 
 
Figure 7. Bar diagram showing the expense per month of brands of 
antihypertensive drugs prescribed as monotherapy 
 
OD: Once daily                               INR:  Indian rupee 
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Avacard AT : Amlodipine 5 mg  + Atenolol 50 mg OD 
Avacard + Lasix : Amlodipine 5 mg  + Furosemide 40 mg OD 
Telmikind H : Telmisartan 40 mg + Hydrochlorothiazide 12.5 mg OD 
Nebistar + Avacard : Nebivolol 5 mg  + Amlodipine 5 mg OD 
Telmikind + Avacard : Telmisartan 40 mg + Amlodipine 5 mg 
Lartan AM : Losartan  50 mg +  Amlodipine 5 mg BD 
Avacard + Ramitorva : Amlodipine 5 mg OD, Ramipril 5 mg + Atorvastatin 10 mg +   
  Aspirin 75 mg OD 
Losar H : Losartan 50 mg + Hydrochlorothiazide 12.5 mg OD 
Cardivas + Ramipril : Carvedilol 3.125 mg + Ramipril 2.5 mg OD 
Envas H : Enalapril 5 mg + Hydrochlorothiazide 12.5 mg OD 
 
Figure 8. Bar diagram showing the expense per month of various brands of 
antihypertensive drugs prescribed as two drug therapy 
OD: Once daily                      BD: Twice daily                       INR: Indian rupee 
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Ramitorva + Amlo AT : Ramipril 5 mg + Atorvastatin 10 mg + Aspirin 75 mg OD, Amlodipine  
  5mg + Atenolol 50 mg OD 
Losar H + Avacard : Losartan 50 mg + hydrochlorothiazide 12.5 mg OD, Amlodipine 5 mg    
  OD 
Telma H + Avacard : Telmisartan 40 mg+ Hydrochlorothiazide 12.5 mg OD, Amlodipine  
  5 mg  BD 
 
Concor + Ramitorva + Lasix : Bisoprolol 2.5 mg BD + Ramipril 5 mg + Atorvastatin 10 mg + Aspirin   
  75 mg OD, Furosemide 20 mg OD 
 
Avacard + Lasix + Aten : Amlodipine 5 mg BD +  Furosemide 40 mg BD + Atenolol 25 mg OD 
 
Telista H + Revelol AM : Telmisartan 40 mg+ Hydrochlorothiazide 12.5 mg OD, Metoprolol  
  50 mg + Amlodipine 5 mg OD 
 
Telma H + Amlokind AT : Telmisartan 40 mg+ Hydrochlorothiazide 12.5 mg OD, Atenolol 50 mg 
+ Amlodipine 5 mg OD 
 
Figure 9. Bar diagram showing expense per month of various brands of 
antihypertensive drugs prescribed as three and four drug combination 
therapy 
OD: Once daily                           BD: Twice daily                           INR: Indian rupee 
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Figure 10. Pie diagram showing the percentage of males and females who 
experienced ADRs due to use of antihypertensive drugs 
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Figure 11.  Bar diagram showing the age wise distribution of patients who 
experienced ADRs due to use of antihypertensive drugs 
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Figure 12. Pie diagram showing the percentage of ADRs experienced in 
patients who received monotherapy and combination therapy of 
antihypertensive drugs 
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Figure 13.  Bar diagram showing the number of ADRs experienced with 
different classes of antihypertensive drugs 
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Figure 14. Bar diagram showing system-wise distribution of ADRs to 
antihypertensive drugs 
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WHO-UMC Causality assessment scale
Certain 
 Event or laboratory test abnormality, with 
plausible time relationship to drug intake 
 Cannot be explained by disease or other 
drugs 
 Response to withdrawal plausible 
 Event definitive pharmacologically or 
phenomenologically 
 Rechallenge satisfactory, if necessary 
Probable/ Likely 
 Event or laboratory test abnormality, with 
reasonable time relationship to drug intake 
 Unlikely to be attributed to disease or other 
drugs 
 Response to withdrawal clinically reasonable 
 Rechallenge not required 
Possible  
 Event or laboratory test abnormality, with 
reasonable time relationship to drug intake 
 Could also be explained by disease or other 
drugs 
 Information on drug withdrawal may be 
lacking or unclear 
Unlikely  
 Event or laboratory test abnormality, with a 
time to drug intake that makes a 
relationship improbable 
 Disease or other drugs provide plausible 
explanations 
Conditional/ Unclassified 
 Event or laboratory test abnormality 
 More data for proper assessment needed, or 
 Additional data under examination 
Unassessable/ Unclassifiable 
 Report suggesting an adverse reaction 
 Cannot be judged because information is 
insufficient or contradictory 
 Data cannot be supplemented or verified 
 
Figure 15. Bar diagram showing the causality assessment of ADRs due to 
antihypertensive drugs by WHO-UMC Causality assessment scale  
 WHO-UMC Causality Categories26 
WHO     :World Health Organization 
UMC      :Uppsala Monitoring Centre 
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S.No. Questionnaires Yes No Do not 
know 
1. Are there previous conclusive reports on this reaction? 1 0 0 
2. Did adverse drug reaction (ADR) appear after the 
suspected drug was administered? 
2 -1 0 
3. Did ADR improve when the drug was discontinued or a 
specific antagonist was administered? 
1 0 0 
4. Did the adverse reaction appear when the drug was 
readministered?  
2 -1 0 
5. Are there any alternative causes (other than the drug) 
that could have caused the reaction?  
-1 2 0 
6. Did the reaction reappear when placebo was given?  -1 1 0 
7. Was the drug detected in the blood (or other fluids) in 
concentration known to be toxic?  
1 0 0 
8. Was the ADR more severe when dose was increased or 
less severe when dose was decreased?  
1 0 0 
9. Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure?  
1 0 0 
10. Was the adverse event confirmed by any objective 
evidence?  
1 0 0 
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Naranjo algorithm or adverse drug reaction probability scale26 - The total score 
calculated from this table defines the category as: Possible (total score 1–4), Probable 
(total score 5–8), Definite (total score >9) 
Figure 16. Bar diagram showing the causality assessment of ADRs due to 
antihypertensive drugs by Naranjo scale 
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Level 1  An ADR occurred but required no change in treatment with the suspected 
drug.  
Level 2 The ADR required that treatment with the suspected drug be held, 
discontinued, or otherwise changed. No antidote or other treatment 
requirement was required. No increase in length of stay.  
Level 3 The ADR required that treatment with the suspected drug be held, 
discontinued, or otherwise changed. AND/OR An antidote or other treatment 
was required. No increase in length of stay.  
Level 4  (A) Any level 3 ADR which increases length of stay by at least 1 day. OR  
(B) The ADR was the reason for the admission.  
Level 5  Any level 4 ADR which requires intensive medical care.  
Level 6 The adverse reaction caused permanent harm to the patient.  
Level 7 The adverse reaction either directly or indirectly led to the death of the 
patient.  
 
Mild
Moderate
Severe
75
11
0
Number of ADRs to antihypertensive drugs
Hartwig severity scale
Figure 17. Bar diagram showing the severity assessment of ADRs due to 
antihypertensive drugs by Hartwig severity scale 
 
Hartwig severity scale28 - according to this scale ADRs were assessed as Mild (level 1, 
2), Moderate (level 3, 4, 5) and Severe (level 6, 7) 
  Results 
102 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
SECTION A  
Answering “yes” to one or more of the following implies that an ADR is DEFINITELY preventable.  
1. Was there a history of allergy or previous reactions to the drug?  
2. Was the drug involved inappropriate for the patient’s clinical condition?  
3. Was the dose, route, or frequency of administration inappropriate for the patient’s age, 
weight, or disease state? 
If answers are all negative to the above, then proceed to Section B  
SECTION B  
Answering “yes” to one or more of the following implies that an ADR is PROBABLY preventable  
1. Was required therapeutic drug monitoring or other necessary laboratory tests not 
performed?  
2. Was a documented drug interaction involved in the ADR?  
3. Was poor compliance involved in the ADR?  
4. Was a preventative measure not administered to the patient? 
5. If a preventative measure was administered, was it inadequate and/or inappropriate? 
Answer ‘NO’ if this question is nonapplicable. 
If answers are all negative to the above, then proceed to Section C  
SECTION C  
The ADR is NOT preventable.  
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Criteria for determining preventability of an adverse drug reaction (ADR) by modified 
Schumock and Thronton preventability scale27  
 
Figure 18. Bar diagram showing the preventability criteria of ADRs due to 
antihypertensive drugs by Schumock and Thornton scale. 
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7. Discussion: 
      This study analysed the drug utilization pattern and ADR profile of 
antihypertensive drugs prescribed in the Department of Medicine, Sree 
Mookambika Institute of Medical Sciences, Kulasekharam, Tamilnadu. 
      In the present study 25.2% patients were male and 74.8% patients were 
female and this was similar to the study done by Khurshid et al.8 In our study 
it was found that hypertension was more prevalent in females than males. 
There is comparatively less risk of hypertension in premenopausal women 
when compared to men.56 Our study showed that common age group of 
patients with hypertension was 61 to 70 years but a study by Tiwari et al.54 
showed that the commonest age group affected was 50 to 60 years. Below 45 
years of age men are more prone for hypertension but above 45 years women 
are more prone for hypertension.18 
      In our study 75.59% of the patients had received monotherapy of 
antihypertensive drug which was similar to the study by Bhradwaj et al.64 and 
Pai et al.52 but Etuk et al.78 showed that two drug combinations are commonly 
prescribed. This difference is commonly due to the doctor’s choice of 
treatment taking into consideration of various factors like patient 
characteristics, presence of any comorbid conditions and the medicine 
availability.78 
      In the present study amlodipine was the most commonly used drug as 
monotherapy in 87.5% of patients. CCBs have very less or no metabolic 
effects which is beneficial for diabetic hypertensive patients and also it is 
cheap. These could be the reasons for it to be the most commonly prescribed 
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drug. DUS of antihypertensive drugs by Maduram et al.55 and John et al.65 also 
showed amlodipine as the most frequently prescribed drug. The 
antihypertensive effect of CCBs are independent of sodium intake or 
concurrent use of NSAIDS which is not the case with ACE inhibitors. In 
patients having hypertension with coexisting nephropathy, CCBs remarkably 
reduce the blood pressure. CCBs are the most preferred drugs in case of 
hypertensive patients with coexisting diabetes mellitus. They also have 
additional natriuretic effect and thus it rules out the need for adding a 
diuretic.17 
      Present study found that amlodipine + atenolol was the most commonly 
prescribed two drug combination in 27.26% of patients which was similar to 
the study done by Joshi et al.4 This could be because the efficacy of 
amlodipine is improved by combining it with β-blockers. By prescribing 
combination drugs, expenditure for the drugs can be minimized and also 
patient compliance may be improved.18 
      This study found that losartan + hydrochlorothiazide + amlodipine was the 
most commonly prescribed three drug combination in 42.84% of the patients 
but Kousalya et al.79 showed enalapril + amlodipine + hydrochlorthiazide as 
the commonest three drug combination. In a study by Bhardwaj et al.64 
showed that none of the patient required three drug therapy. 
      The present study observed that monotherapy of antihypertensive drugs 
was more common than multiple drug therapy. But Janagan et al.56 showed 
that combination therapy was more common than monotherapy. 
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      Diuretics are the first line drugs in treatment of hypertension according to 
JNC 780 guidelines. But NICE guidelines81 on the management of primary 
hypertension in adults recommends ACE inhibitor or ARB as initial treatment 
of hypertension under 55 years. But if patients are more than 55 years then 
CCBs are used as first line drugs. Diuretics should be used as first choice 
drugs only if CCBs are contraindicated in the patient or if the patient has 
developed oedema or if patient is at risk of developing heart failure. In our 
study CCB was the most commonly used drug and diuretic was prescribed 
less frequently. 
      In this study all the antihypertensive drugs were prescribed by brand name 
and none by generic name which is not a good indicator of rational 
prescription. Provision of drugs in their generic name, prescribing from EDL 
and rational drug prescribing of drugs are recognized measures that can 
considerably reduce the expenditure for drugs to patients. In this way 
treatment standard will be maintained and will help to attain optimal control of 
hypertension. Prescriptions by brand name will help to reduce the drug 
expenses and will also rationalise prescriptions.82 
      One of the important factors which affects patient compliance and drug 
adherence is the occurrence of adverse drug reactions. In the present study, 
out of 86 ADRs recorded, 63.95% were female and 36.05% were male. 
Theoretically women were thought to be at greater risk of adverse drug 
reactions than men, which might be due to gender related differences in 
pharmacokinetics, immunology and hormonal factors. Rational adjustment of 
dose will help to minimise ADRs in females. 
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      In our study, ADRs were found to be more common in age group of 61 to 
70 years which was similar to the study by Solanki et al.19 It was found that 
elderly patients are more prone to ADRs than younger patients. 
      In our study most common system associated with ADRs was central 
nervous system; but Hussain et al.67 study reported cardiovascular system as 
the commonly affected system. In our study ADRs also involved musculo-
skeletal system, respiratory system, gastrointestinal system, cardiovascular 
system and skin. This study showed that different patterns of prescriptions of 
antihypertensive drugs produced different types of ADRs.  
      As anticipated, patients who received combination therapy were 
associated with more number of ADRs (58.14%) as compared to patients who 
were on monotherapy (41.86%). Use of multiple drugs in hypertension should 
be avoided as there are higher chances of developing ADRs and it may also 
cause drug interactions. Only the absolutely essential medicines should be 
prescribed for treatment of hypertension. 
      In the current study, CCBs were the common group of antihypertensive 
drugs associated with ADRs (62.79%) which was similar to the study by Basak 
et al.76 In CCBs, amlodipine was found to be the commonest drug associated 
with ADRs. The most common individual ADR was headache which was seen 
in 20.93% of the patients which was similar to the study done by Alomar et 
al.74 This could be due to arteriolar vasodilatation caused by CCBs. CCBs are 
also not suitable in patients with left ventricular dysfunction due to their 
negative inotropic effect.18 In our study peripheral oedema is also one of the 
common ADR seen with the use of CCBs. It occurs due to precapillary dilation 
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and reflex post capillary constriction causing increase in hydrostatic 
pressure.18    
      Our study showed that according to WHO causality assessment scale 
51.16% of the ADRs were probable which means that these reactions are 
caused by the use of antihypertensive drugs and not due to any disease or by 
the use of other drugs and clinical improvement is seen when the drug is 
dechallenged. Possible ADRs were seen in 32.56% of the patients which 
could be due to presence of a disease or simultaneous use of other drugs. 
      The causality assessment by Naranjo scale showed that 77.91% ADRs 
were Possible. Naranjo scale helps to determine whether ADR is due to the 
drug or due to other factors. A study done by Rende et al.72 showed a probable 
association in 92% and a possible association in 8%. 
     In our study Modified Hartwig and Siegel’s scale was used to assess the 
severity of ADRs.  According to this scale 87.21% of ADRs were mild and this 
was in accordance with the study done by Hussain et al.67 
      In the present study Modified Schumock and Thornton scale was used to 
assess the preventability of ADRs and it was found that 66.28% of ADRs were 
definitely preventable but Haile et al.83 In his study showed that majority of the 
ADRs were probably preventable. Our study showed that elderly individuals 
were at high risk of developing ADRs and most of the ADRs were preventable. 
Prescribing doctors should have sound knowledge regarding the basic 
pharmacology and how age affects pharmacokinetics of the drugs which will 
help to prevent various ADRs. 
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8. Conclusion:  
      In a cross-sectional study conducted in this institute during the period from 
October 2013 to March 2014 to evaluate the drug utilization pattern of 
antihypertensive drugs it was seen that 75.59% of drug prescriptions were by 
monotherapy and 24.41% by combination therapy and all the prescriptions 
were found to be rational. The study also showed that all the prescriptions were 
by brand name. The pharmacoeconomics of the antihypertensive drugs 
prescribed in the study revealed furosemide as the least expensive and 
metoprolol as the most expensive drugs prescribed as monotherapy. In the 
combination therapy the least expensive was amlodipine with furosemide and 
most expensive was the combinations of telmisartan, hydrochlorothiazide and 
amlodipine.      
      In this study the ADRs were found probable (51.16%), possible (32.56%), 
unclassifiable (11.63%) and unlikely (4.65%) by using WHO causality 
assessment scale. By using Naranjo algorithm scale it was found that ADRs 
were possible in 77.91% and probable in 22.09% of cases. Modified Schumock 
and Thornton scale for preventability of ADRs showed that ADRs were 
definitely preventable in 33.72% and probably preventable in 66.28% of cases. 
Modified Hartwig and Siegel scale for severity of ADRs showed that 87.21% of 
the ADRs reported were mild and 12.79% were moderate. This study also found 
that amlodipine was responsible for most of the ADRs and among all the ADRs 
reported headache was the commonest followed by dizziness, pedal oedema, 
fatigue, abdominal pain, dry cough, breathlessness, bradycardia, muscle 
cramps, sedation, diarrhoea and irritation all over the body.       
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9. Summary: 
      The present cross-sectional study was undertaken to study the drug 
utilization pattern in patients with hypertension and to analyse the adverse 
drug reaction profile of antihypertensive drugs. The study was conducted for 
a period of 6 months. The data was collected using a case record form. The 
study included patients of all age group.  
      A total of 127 prescriptions of patients receiving antihypertensive drugs 
from Medicine department were collected. Commonest age group of the 
patients was 61-70 years. The incidence of hypertension in females (74.8%) 
was found to be more than males (25.2%). All the antihypertensive drugs were 
prescribed by brand name. Monotherapy (75.59%) was preferred more than 
combination therapy (24.41%). Amlodipine was the most commonly 
prescribed drug as monotherapy. Amlodipine with atenolol was the most 
commonly prescribed combination therapy. Metoprolol was the most 
expensive and furosemide was the least expensive drug prescribed as 
monotherapy. Telmisartan with hydrochlorothiazide and amlodipine was the 
most expensive and amlodipine with furosemide was the least expensive 
drugs prescribed as combination therapy. The overall analysis of the 
prescription patterns is suggestive of rational prescribing practices in the 
selection of suitable antihypertensive drugs.  
      A total of 86 ADRs to antihypertensive drugs were also collected during 
the study period. Majority of the ADRs were in females (63.95%) followed by 
males (36.05%). Most common age group affected by ADRs was 61-70 years. 
Patients receiving combination therapy (58.14%) of antihypertensive drugs 
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were more frequently associated by ADRs than patients on monotherapy 
(41.86%). CCBs was found to be the most common class of antihypertensive 
drugs associated with ADRs. Most common system associated with ADRs 
was central nervous system. Headache was the most common individual ADR 
followed by dizziness, pedal oedema, fatigue, abdominal pain, dry cough, 
breathlessness, bradycardia, muscle cramp, sedation, diarrhoea and irritation 
all over the body. 
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CONSENT FORM 
    PART 1 OF 2 
                   INFORMATION FOR PARTICIPANTS OF THE STUDY 
 
DEAR VOLUNTEERS, 
      We welcome you and thank you for your keen interest in participation in this research 
project. Before you participate in this study, it is important for you to understand why this 
research is being carried out. This form will provide you all the relevant details of this 
research. It will explain the nature, the purpose, the benefits, the risks, the discomforts, the 
precautions and the information about how this project will be carried out. It is important 
that you read and understand the contents of the form carefully. This form may contain 
certain scientific terms and hence, if you have any doubts or if you want more information, 
you are free to ask the study personnel or the contact person mentioned below before you 
give your consent and also at any time during the entire course of the project. 
 
1. Name of the Principal Investigator:         Dr. A. Navaneeth 
            Postgraduate 
            Department of Pharmacology 
            SMIMS, Kulasekharam 
 
2. Name of the Guide:                 Dr. Rema Menon. N (MD) 
             Professor and Head 
             Department of Pharmacology 
             SMIMS, Kulasekharam 
 
3. Name of the Co-Guides:                   Dr. Kaniraj Peter (MD) 
            Professor and Head 
            Department of Medicine 
            SMIMS, Kulasekharam                   
                   
                  Dr. Madhavrao (MD) 
              Assistant Professor 
              Department of Pharmacology 
              SMIMS, Kulasekharam 
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4. Institute:   
      Sree Mookambika Institute of Medical Sciences, Kulasekharam 629161, 
Kanyakumari district, Tamilnadu. 
5. Title of the study:  
       A Study of Drug Utilization Pattern and Adverse Drug Reaction Profile of 
Antihypertensive Drugs Prescribed in A Tertiary Care Hospital. 
6. Background information:  
      Prevalence of hypertension is progressing rapidly worldwide. Response to 
antihypertensive drugs varies in different population. Drug utilization research 
establishes the current trend in the use of antihypertensive drugs and adverse drug 
reaction including the new drug and to identify irrational prescription. Irrational 
prescription can affect the adherence to drugs thereby not reaching therapeutic goal 
ultimately rising the economic burden. Since you are diagnosed to be hypertensive and 
on treatment with antihypertensive drugs it is proposed to do the study to evaluate the 
drug utilization pattern and adverse drug reactions of antihypertensive drugs in the 
Medicine department of this institution. 
7. Aims and objectives:  
      To assess the following in the Department of Medicine, Sree Mookambika Institute 
of Medical Sciences, Kulasekharam, Tamilnadu during the period from October 2013 
to March 2014: 
i. The pattern of prescription of antihypertensive drugs as monotherapy and 
combination therapy  
ii. The pattern by brand name and generic names  
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iii. The pharmacoeconomics of antihypertensive drugs prescribed 
iv. Rationality of antihypertensive drugs prescribed 
v. The adverse drug reaction profile of antihypertensive drugs 
8. Scientific justification of the study:  
      Drug utilization research establish current trend in the use of antihypertensive drugs 
and adverse drug reactions including the new drug and to identify irrational prescription. 
Irrational prescription can affect the adherence to drugs thereby not reaching therapeutic 
goal ultimately rising the economic burden. Till date no study on drug utilization pattern 
and adverse drug reaction profile of antihypertensive drugs is conducted in this 
institution. Hence it has been proposed to conduct the study to evaluate the drug 
utilization pattern and adverse drug reaction profile of antihypertensive drugs in the 
Medicine department of this institution.  
9. Procedure for the study:  
      The study will be carried out after getting informed written consent from each 
participant. The study will not have any impact on the treatment given by physician. 
Study will be carried out in collaboration with the Medicine department. Enrolled 
subject name, age, sex, co-morbid condition and treatment if any will be recorded in a 
predesigned case record form. Details of the prescribed antihypertensive drug(s) will be 
recorded. Conclusion of the study will be made from the details in the case record form. 
10. Expected risks for the participants:  
      This study does not involve any risk to the participant. 
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11. Expected benefits of research for the participants:  
      This study does not provide any direct benefit to the participant, however the data 
obtained from the study will be useful for better medical health care in the future. 
12. Maintenance of confidentiality:  
       Will be maintained. 
13. Why have I been chosen to be in this study?  
      You are diagnosed as hypertensive and prescribed with antihypertensive drugs, hence 
according to the inclusion and exclusion criteria you are recruited into this study. 
14. Agreement of Compensation to the participants (In case of a study related 
injury): 
      Not applicable 
16. Anticipated prorated payment, if any, to the participant(s) of the study:  
      No 
17. Can I withdraw from the study at any time during the study period? 
      The study participant can withdraw from the study at any time and will not involve 
any penalty or loss of benefits to which the participant is otherwise entitled. 
18. If there is any new findings / information, would I be informed?  
      Yes 
19. Expected duration of the Participant’s participation in the study:  
      1 day 
20. Any other pertinent information:  
No 
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21. Whom do I contact for further information? 
For any study related queries, you are free to contact 
 
Dr. A. Navaneeth 
Post Graduate 
Department of Pharmacology 
SMIMS 
Mobile number: 9626421444 
Email:navneetpraveen@gmail.com 
 
 
Place: Kulasekharam 
 
                     Signature of  the  Principal Investigator 
Date :  
                       Signature of the Participant 
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CONSENT FORM 
 
PART 2 OF 2 
 
PARTICIPANTS CONSENT FORM 
 
      The details of the study have been explained to me in writing and the details have been 
fully explained to me. I am aware that the results of the study may not be directly beneficial 
to me but will help in the advancement of medical sciences. I confirm that I have 
understood the study and had the opportunity to ask questions. I understood that my 
participation in the study is voluntary and that I am free to withdraw at any time, without 
giving any reason, without the medical care that will normally be provided by the hospital 
being affected. I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). I have been given an information sheet 
giving details of the study. I fully consent to participate in the study titled ‘A study of drug 
utilization pattern and adverse drug reaction profile of antihypertensive drugs 
prescribed in SMIMS’. 
 
Serial no/Reference no: 
 
Name of the Participant:        Address of the Participant: 
 
 
 
 
 
 
 
 
 
 
Signature of the participant 
 
Witnesses: 
 
1. 
 
 
2. 
 
Date: 
 
Place: Kulasekharam 
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Sree Mookambika Institute of Medical Sciences 
Department of Pharmacology 
Case Record Form 
Serial number: 
Name:                                                                                                     Date: 
 
Age:                                           Sex: M / F                                            OPD No. : 
Occupation:                               Socioeconomic status: 
Address with contact number: 
 
Diagnosis: 
 
Duration:                                                   BP:                                  BP (Previous visit): 
 
Any co-existing disease? Yes / No. (If yes then details) 
 
 
Any other concurrent medication used? Yes / No. (If yes then details) 
 
 
Prescription details: 
 
 
S.No 
Name of 
the drug 
prescribed 
 
Formulation 
 
Dose 
 
Route 
 
Frequency 
 
Duration 
 
Before/After 
Food 
 
Cost 
in 
INR 
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            Adverse drug reactions reported by patients:                    
(If adverse reaction experienced details will be filled up in CDSCO ADR form) 
            
     
Adverse drug reaction  Experienced/Not experienced 
Nausea, Vomiting  
Dizziness, Headache  
Cough  
Oedema  
Erectile dysfunction  
Diarrhoea  
Dyspnoea  
Fatigue  
Hallucinations  
Any other ADRs  
                                                                  
             
                                                      
Place: Kulasekharam           
                                                              
Date:                                                                     Signature of the Principal Investigator                                                                                                                                                                                                                                                           
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Abbreviations 
ACE :Angiotensin converting enzyme 
ADCR :Adverse cutaneous drug reactions  
ADR :Adverse drug reaction  
AIPs :Aldosterone-induced proteins 
Ang I :Angiotensin I 
Ang II :Angiotensin II 
ANS :Autonomic nervous system  
AP :Action potential 
ARB :Angiotensin receptor blocker 
AT1 :Angiotensin II receptor, type 1 
AT2 :Angiotensin II receptor, type 2 
BMI :Body mass index 
BP :Blood pressure 
BPH :Benign prostatic hyperplasia 
CAD :Coronary artery disease 
cAMP :Cyclic adenosine monophosphate 
CBA :Cost benefit analysis 
CCB :Calcium channel blocker 
CDSCO :Central Drugs Standard Control Organization 
CEA :Cost effectiveness analysis 
CHF :Chronic heart failure 
CMA :Cost minimization analysis 
COPD :Chronic obstructive pulmonary disease 
COX-2 :Cyclooxygenase-2 
CUA :Cost utility analysis 
CVA :Cerebrovascular accident  
DA :Dopamine 
DASH :Dietary Approaches to Stop Hypertension 
DCT :Distal convoluted tubule 
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DHPs :Dihydropyridines  
DM :Diabetes mellitus 
DUS :Drug utilization studies  
ECF :Extracellular fluid 
EDL :Essential drug list 
FDC :Fixed dose combination 
G proteins :Guanosine nucleotide binding regulatory proteins 
GFR :Glomerular filtration rate 
HDL :High density lipoprotein 
ISH :International Society of Hypertension 
JNC 7 :Joint National Committee-7 
LDL :Low density lipoprotein 
LVH :Left ventricular hypertrophy 
MAO :Monoamine oxidase 
MI :Myocardial infarction 
NICE :National Institute for Health and Clinical Excellence 
NSAIDS :Nonsteroidal Antiinflammatory Drugs 
PVR :Peripheral vascular resistance 
RAAS :Renin angiotensin aldosterone system 
TPR :Total peripheral resistance  
UMC :Uppsala Monitoring Centre 
VMAT :Vesicular monoamine transporter  
WHO :World health organisation 
  
 
